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The phosphoinositide 3-kinase (PI3K) pathway is a central signal transduction axis con-
trolling normal B cell homeostasis and activation in humoral immunity. The p110δ PI3K
catalytic subunit has emerged as a critical mediator of multiple B cell functions. The activ-
ity of this pathway is regulated at multiple levels, with inositol phosphatases PTEN and
SHIP both playing critical roles. When deregulated, the PI3K pathway can contribute to
B cell malignancies and autoantibody production. This review summarizes current knowl-
edge on keymechanisms that activate and regulate the PI3K pathway and inﬂuence normal
B cell functional responses including the development of B cell subsets, antigen presenta-
tion, immunoglobulin isotype switch, germinal center responses, andmaintenance of B cell
anergy.We also discuss PI3K pathway alterations reported in select B cell malignancies and
highlight studies indicating the functional signiﬁcance of this pathway in malignant B cell
survival and growth within tissuemicroenvironments. Finally, we comment on early clinical
trial results, which support PI3K inhibition as a promising treatment of chronic lymphocytic
leukemia.
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INTRODUCTION: THE PHOSPHOINOSITIDE 3-KINASE
PATHWAY IN LYMPHOCYTES
Phosphoinositide 3-kinases (PI3K) are a family of enzymes that
selectively phosphorylate the D3 hydroxyl group of the inosi-
tol head group of phosphoinositide (PI) lipids. PI3K enzymes
can be divided into three families based on their structure and
PI speciﬁcity. Class I PI3K enzymes are heterodimeric com-
plexes composed of regulatory (p85α, p85β, p55γ, p55α, p50α,
and p101) and catalytic (p110α, p110β, p110δ, or p110γ) sub-
units. Class I PI3K enzymes can generate two major species
of D3 phosphoinositides, PI(3,4,5)P3 and PI(3,4)P2. Class II
PI3K enzymes selectively phosphorylate PI and PI(4)P to pro-
duce PI(3)P and PI(3,4)P2, whereas class III only produce PI(3)P
(Deane and Fruman, 2004). Little is known about the role of class
II and III PI3Ks in lymphocytes and they will not be reviewed
here. The accumulation of PI(3,4,5)P3 and PI(3,4)P2 are fur-
ther controlled by PI phosphatases, including phosphatase and
tensin homolog (PTEN) and SH2 domain-containing inositol-
5′-phosphatase 1 (SHIP1 or SHIP). Speciﬁc binding of intra-
cellular signaling enzymes and scaffold proteins to PI(3,4,5)P3
and PI(3,4)P2 are thought to mediate the functional outcomes
triggered by these second messengers molecules. Collectively
we refer to PI3K enzymes, PI phosphatases, D3 phosphoinosi-
tides, and their direct binding partners as the PI3K pathway
(Figure 1). The cellular responses triggered by the PI3K pathway
are highly inﬂuenced by integration with other signals that can
directly impact PI-binding proteins and also modify downstream
events.
Substantial evidence now exists indicating that development
and activation of B lymphocytes is highly dependent on the PI3K
pathway. Mature B cell survival and maintenance requires contin-
uous expression of a signaling-competent B cell antigen receptor
(BCR) which is thought to support a basal level of “tonic” sig-
naling (Lam et al., 1997; Tze et al., 2005). Enforced PI3K activity
was found to promote survival of mature B cells in the absence
of BCR expression (Srinivasan et al., 2009). Abundant evidence
has emerged indicating that activation of the PI3K pathway is
required for B cell survival and differentiation into mature B cell
subsets, as well as a number of mature B cell immune functions.
In addition to functions in normal B cells, several types of B cell
malignancy show evidence of deregulation of the PI3K pathway.
Moreover, some malignant B cells appear to be dependent on this
pathway for survival and retention in protective lymphoid tissue
niches.
The functional and potential clinical importance of this path-
way continues to drive research into molecular regulation of this
pathway in B cells. While many components of are conserved
among cell types, lymphocytes appear to have a few unique
modiﬁcations of the core pathway. While the p110α and β cat-
alytic subunits are ubiquitously expressed, the p110δ and p110γ
are largely restricted to leukocytes (Chantry et al., 1997; Van-
haesebroeck et al., 1997). Class IA PI3K enzymes such as p110δ
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FIGURE 1 | Major components of the PI3K pathway in B cells
discussed in this review. PI3K pathway activation via B cell antigen
receptor is depicted schematically. Lyn and Syk are recruited to the
engaged BCR where they are activated by phosphorylation and initiate the
downstream signaling cascade. Class I PI3K such as p110δ or p110α binds
phosphorylated CD19 and catalyzes the production of PIP3. Alternative
PI3K recruitment mechanisms not shown include binding to BCAP, TC21,
or IRS-2/IL-4R. Several PH domain-containing signaling proteins bind to
PIP3 including enzymes such as Btk and Akt and adaptor proteins such as
Bam32. PIP3 levels are down-regulated by phosphatases PTEN and SHIP.
PTEN directly opposes the PI3K reaction while SHIP, classically activated
downstream of FcγRIIB co-aggregation with the BCR, produces a novel
second messenger PI(3,4)P2 which can recruit its own set of PH domain
proteins. Recruited PI-binding proteins are enzymatically activated and/or
serve to form membrane-associated protein complexes that regulate
downstream signaling and cytoskeletal rearrangement.
are classically thought to be activated by tyrosine kinase-linked
receptors whereas class 1B PI3K (p110γ) is activated through G
protein-coupled receptors (Deane and Fruman, 2004). Consistent
with this model, the weight of evidence suggests that p110γ is not
essential for B cell signaling via antigen (Ag) and cytokine recep-
tors (Reif et al., 2004; Beer-Hammer et al., 2010). However, a more
complex picture has emerged regarding p110δwhich seems to have
some involvement in signaling via G protein-coupled chemokine
receptors. Immune cells also selectively express the PI phosphatase
SHIP1, and some PI-binding proteins such as Bam32/DAPP1 and
Btk. These molecules appear to have regulatory functions speciﬁc
to immune cells and clearly function in B cells. The goal of this
review is to bring together for discussion the current evidence on
molecular regulation and cellular functions of the PI3K pathway
in the context of normal and malignant B cells.
MECHANISMS OF PI3K PATHWAY ACTIVATION
IN NORMAL B CELLS
CONTROL OF PI3K ENZYMATIC ACTIVITY
Class IA PI3Ks at rest exist predominantly in an inhibited con-
formation. The p110 catalytic subunit constitutively associates
with the regulatory subunit via its interstitial SH2 domain (iSH2).
This iSH2 bridges two other SH2 domains, the N-terminal
and C-terminal SH2 domains (nSH2 and cSH2, respectively),
which also associate weakly with p110 and promote an inhibited
conformation (Yu et al., 1998b). Activation of catalytic activity
involves binding of nSH2 and cSH2 to phosphopeptide motifs
such as pTyr-x-x-Met. This binding both recruits the complex
to the membrane and dissociates these SH2 domains from p110,
relieving their inhibitory effect (Carpenter et al., 1993; Yu et al.,
1998b). Intriguingly, the precise mechanism of regulation by p85
may differ between p110 isoforms (Burke et al., 2011). It was previ-
ously shown for p110α that the minimal p85 domains required for
inhibition are the nSH2 plus iSH2, where nSH2 is responsible for
reversible inhibition in the absence of phosphopeptide binding
(Yu et al., 1998a). More recently, it has been demonstrated that
p110δ and p110β have a distinct mechanism of inhibition involv-
ing cSH2 in addition to nSH2 (Burke et al., 2011; Zhang et al.,
2011), suggesting differential regulation of these isoforms by
cSH2-binding phosphopeptide ligands. Recent evidence suggests
that binding of p110 itself to anionic lipids in the cell mem-
brane contributes to enhancement of catalytic activity for all Class
IA isoforms. Access to these lipids is regulated by p85 and, at
least for p110α, seems to confer a global conformational change
(Hon et al., 2011). Binding of the catalytic subunit to certain
Ras family GTPases at the membrane also contributes to acti-
vation (Rodriguez-Viciana et al., 1994, 2004; Jimenez et al., 2002).
Interestingly, p110 isoforms show selectivity in activation by dis-
tinct Ras family members, with p110δ showing selective activation
by R-Ras1 and R-Ras2 (Rodriguez-Viciana et al., 2004). TC21/R-
Ras2 has recently been shown to act by mediating an interaction
between the BCR and both p110δ and p85α, thereby recruiting
P13K to the cell membrane (Delgado et al., 2009).
Phosphoinositide 3-kinase is activated downstream of BCR lig-
ation in a manner dependent on the src family kinase Lyn and
sustained by the tyrosine kinase Syk (Kurosaki et al., 1994; Beitz
et al., 1999). Ag binding to the BCR induces tyrosine phosphoryla-
tion of the cytoplasmic tails of the associated signaling chains, Ig-α
and Ig-β by Lyn and Syk (Kurosaki et al., 1994; Beitz et al., 1999). It
has been proposed that both a conformational change in the recep-
tor and a change in the local lipid environment may be required
for this signal initiation step (Tolar et al., 2005). Lyn and Syk also
phosphorylate CD19 (Tuveson et al., 1993; Fujimoto et al., 2000)
and B cell adaptor protein BCAP (Okada et al., 2000; Yamazaki
et al., 2002; Aiba et al., 2008). These both co-aggregate with the
BCR complex in the cell membrane and directly bind p85 via
YxxM motifs. CD19 and BCAP are reported to make complemen-
tary and functionally important contributions to PI3K activation
in B cells (Aiba et al., 2008), with CD19 ligation via the comple-
ment receptor functioning to reduce the threshold of Ag required
to trigger B cell activation (Carter and Fearon, 1992; Buhl et al.,
1997; Wang et al., 2002). The guanine nucleotide exchange fac-
tor Vav is required for PI3K pathway activation downstream of
BCR–CD19 co-ligation but not BCR ligation alone (Vigorito et al.,
2004). Recent studies suggest the adaptor protein Grb2 is required
for efﬁcient PI3K signaling in B cells, however the mechanism is
not yet clear (Ackermann et al., 2011).
Receptors other than the BCR can also induce PI3K signal-
ing in B cells. PI3K is clearly activated by IL-4R and p110δ is
required for functional responses to IL-4 (Bilancio et al., 2006).
PI3K recruitment and activation downstream of the IL-4 receptor
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seems to be mediated primarily by insulin receptor substrate
(Zamorano et al., 1996). Activation downstream of the IL-3 recep-
tor has been shown in some systems to involve binding of p85
to the adaptor protein Gab2 which localizes to activated cytokine
receptors via a Shc–Grb2–Gab2 complex (Gu et al., 2000). Activ-
ity downstream of Toll-like receptors has also been reported and
seems to be mediated by BCAP (Ni et al., 2012; Troutman et al.,
2012). PI3K activation downstream of CD40 ligation depends on
casitas B-lineage lymphoma (c-CBL), acting as an adaptor protein
(Arron et al., 2001). B cell activating factor (BAFF) binding to its
receptor on B cells is reported to induce p110δ activation (Patke
et al., 2006; Henley et al., 2008), however the mechanism is yet to
be characterized.
CONTROL OF PI PHOSPHATASE ACTIVITY
PTEN activity is regulated by a variety of mechanisms, includ-
ing interactions with lipids and proteins, regulation of protein
levels, serine/threonine phosphorylation, and catalytic inactiva-
tion by reactive oxygen species (ROS). In vitro studies revealed
that dynamic binding of the N-terminus of PTEN to anionic
lipids, especially the PTEN substrate PI(4,5)P2, leads to a con-
formational change and an increase in PTEN phosphatase activ-
ity (McConnachie et al., 2003). PTEN protein is sensitive to
regulation by ubiquitination followed by proteasomal degrada-
tion (Wang et al., 2007). Interestingly, monoubiquitination has
also been reported and was shown to promote nuclear import
(Trotman et al., 2007). PTEN levels can also be controlled post-
transcriptionally by the microRNA cluster miR-17-92 (Rao et al.,
2011). Serine/threonine phosphorylation appears to be a dou-
ble edged sword in terms of PTEN regulation, with the outcome
depending on the precise site. Deletion of the C-terminal tail of
PTEN, which contains several phosphorylation sites, revealed a
role both in dampening catalytic activity and increasing protein
stability (Vazquez et al., 2000). The effect on catalytic activity was
later proposed to be the result of a conformational change induced
by phosphorylation (Vazquez et al., 2001; Odriozola et al., 2007),
while the effect on stability is due to protection from proteasomal
degradation (Torres and Pulido, 2001). A study in Jurkat T cells
provided evidence for a feedback loop involving phosphorylation
of Thr366 by GSKβ, a downstream effector of PI3K, which was
reported to inhibit PTEN activity (Al-Khouri et al., 2005). Thr366
phosphorylation was also found to decrease PTEN stability in
glioblastoma cell lines (Maccario et al., 2007). One particularly
interesting PTEN-binding protein that seems to directly promote
its enzymatic activity is p85α, the regulatory subunit classically
associated with the PI3K p110 subunit (Taniguchi et al., 2006;
Chagpar et al., 2010).
A number of reports show that PTEN activity can be regulated
by ROS. Speciﬁcally, oxidation by either exogenous or endoge-
nous H2O2 leads to the formation of a disulﬁde bond between
cysteine 124, found in the active site, and cysteine 71 (Lee et al.,
2002). ROS can be produced in B cells by NADPH oxidase activ-
ity triggered downstream of various receptors (Hancock et al.,
1990; Lee and Koretzky, 1998). Our group demonstrated that
treatment of B cell lines with H2O2 lead to selective accumu-
lation of PI(3,4)P3-speciﬁc pleckstrin homology (PH) domains
at the cell membrane. A synergistic effect was observed with
co-stimulation through the BCR. This is consistent with a role
for H2O2 in the catalytic inactivation of PTEN but not SHIP
(Cheung et al., 2007). Since hydrogen peroxide has been proposed
as a signiﬁcant “second messenger” for B cell activation (Reth,
2002), and ROS production by neutrophils and macrophages is
a ubiquitous component of inﬂammation, oxidative inactivation
of PTEN may be an important mechanism contributing to PI3K
pathway activation in infectious disease and chronic inﬂammatory
disease. All of these regulatory mechanisms, including binding
to lipid and protein partners, degradation, post-transcriptional
repression, Ser/Thr phosphorylation, and inactivation by ROS,
have been described; however their relative importance in B cells
remains to be determined.
SHIP phosphatase activity is regulated at the levels of expres-
sion, sub-cellular localization, phosphorylation, and conforma-
tion. Expression levels can be altered either by translational inhibi-
tion mediated by the microRNA miR-155 (Costinean et al., 2009)
or by ubiquitin-mediated proteasomal degradation (Ruschmann
et al., 2010). The principal activation mechanism of SHIP catalytic
function seems to be recruitment to the cell membrane where it
can access its substrate, PI(3,4,5)P3 (Phee et al., 2000). Classically,
this is accomplished by binding of its SH2 domain to phosphory-
lated immunoreceptor tyrosine-based inhibitory motifs (ITIMs)
in the cytoplasmic tail of the inhibitory receptor FcγRIIBwhen this
receptor is co-engaged with the BCR (Tridandapani et al., 1997).
In mice, another C-terminal tyrosine residue outside the ITIM in
FcγRIIB is reported to be required for SHIP binding as it allows
the formation of a stabilized tri-molecular complex that includes
Grb2 and/or Grap (Isnardi et al., 2004). In human FcγRIIB, the
corresponding C-terminal sequence contains no tyrosine residue,
however the segment itself is required for SHIP binding (Isnardi
et al., 2006). These studies support earlier reports that the C-
terminus of SHIP, containing both a proline rich region as well
as several phosphorylation sites, is required in addition to the
minimal phosphatase domain to efﬁciently mediate downstream
inhibition of Ca2+ ﬂux (Aman et al., 2000).
Although SHIP mediates the inhibitory functions of FcγRIIB
in B cells (Isnardi et al., 2006), SHIP can also act independently
of FcγRIIB to regulate signaling via the BCR and other receptors
(Brauweiler et al., 2000). In many cases, the proteins responsible
for recruitment of SHIP to the membrane are uncharacterized,
however there are reports that SHIP can bind ITAMs in recep-
tors such as FcγRIIA (Maresco et al., 1999), FcεRI (Kimura et al.,
1997), and perhaps the Ig-α chain of the BCR under some condi-
tions (Mukherjee et al., 2012). Once recruited to the membrane,
SHIP is phosphorylated on tyrosine residues in its C-terminus by
Lyn kinase (Tridandapani et al., 1997; Phee et al., 2000). Although
the C-terminal segment is required for full enzymatic activation
(Aman et al., 2000) and tyrosine phosphorylation, especially at
Tyr1020 has been frequently used as a functional readout, it seems
that it does not directly promote 5′-phosphatase activity (Phee
et al., 2000). The main function of phosphorylation at Tyr1020
may be to allow association with SHC and DOK1 (Tridanda-
pani et al., 1997; Tamir et al., 2000), however it is unclear how
these associations can affect the membrane association or cat-
alytic activity of SHIP. On the other hand, the role of speciﬁc
interactions in promoting adaptor functions of SHIP have been
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described (Tridandapani et al., 1997; Tamir et al., 2000). More-
over, phosphorylation of Tyr1020 in response to long-term IL-4
stimulation has been shown to promote proteasomal degradation
of SHIP (Ruschmann et al., 2010).
Contrary to tyrosine phosphorylation, phosphorylation on ser-
ine 440 in the phosphatase domain of SHIP by protein kinase
A can directly enhance catalytic activity in B cells (Zhang et al.,
2009a, 2010a). A recently described model proposes that the SHIP
SH2 domain can bind its tyrosine-phosphorylated C-terminal
tail potentially generating an auto-inhibited conformation. This
implies that other phosphopeptide motifs must compete with
the SHIP C-terminus for binding to the SHIP SH2 domain
(Mukherjee et al., 2012). Another proposed regulatory mecha-
nism is allosteric activation induced by PI(3,4)P2 binding through
SHIP’s C2 domain (Ong et al., 2007). This model suggests a poten-
tial “feed-forward” activation of SHIP by its product that can
be exploited by SHIP-activating compounds (Ong et al., 2007).
All of these regulatory mechanisms, including control of protein
expression, localization, phosphorylation on tyrosine and ser-
ine, and conformational state, likely contribute to SHIP function
in B cells.
PHOSPHOINOSITIDE DYNAMICS AND REGULATION
BY PI PHOSPHATASES
PI3K activation through BCR ligation leads to a transient increase
in PI(3,4,5)P3 (PIP3) andPI(3,4)P2 inB cell lines (Gold andAeber-
sold, 1994; Fruman and Bismuth, 2009). PIP3 levels peak after
approximately 1min and return to baseline after 10min inprimary
mouse B cells (Clayton et al., 2002). The PI3K reaction producing
PIP3 can be directly antagonized by PTEN (Maehama and Dixon,
1998; Anzelon et al., 2003). Later, it was conﬁrmed that PI(3,4)P2
can be generated either from direct phosphorylation of PI(4)P
by PI3K or from dephosphorylation of PIP3 by SHIP (Brauweiler
et al., 2000). Brauweiler et al. (2000) showed that PIP3 is transiently
produced after BCR ligationwhile PI(3,4)P2 levels increase steadily
over a much longer period of time, consistent with earlier studies
inB cell lines (Gold andAebersold,1994). In SHIP-deﬁcientB cells,
however, PIP3 levels are dramatically increased and sustained
while PI(3,4)P2 production is signiﬁcantly abrogated (Brauweiler
et al., 2000). In the human BJAB B cell line we found that BCR-
induced PIP3 responses are rapid and transient, while PI(3,4)P2
responses are relatively delayed and sustained (Marshall et al.,
2002) and veriﬁed that stimulation of B cell lines under condi-
tions that promote SHIP activity results in reduced PIP3 levels
and a dampening of downstream pathways dependent on PIP3
(Krahn et al., 2004).
Although the action of both SHIP and PTEN antagonizes PI3K
signaling by consuming PIP3, the SHIP product PI(3,4)P2 is itself
a second messenger subject to further regulation by inositol 4′-
phosphatases (Norris and Majerus, 1994; Gewinner et al., 2009).
While PTEN can also efﬁciently dephosphorylate PI(3,4)P2 in
vitro, limited evidence exists for PTEN regulation of PI(3,4)P2
levels in vivo. Stimulation of cells with H2O2, which inacti-
vates PTEN and 4-phosphatases but not SHIP (Leslie et al., 2003;
Ross et al., 2007), leads to a selective accumulation of PI(3,4)P2
(Van der Kaay et al., 1999). Thus differential regulation of PIP3
and PI(3,4)P2 dynamics under different stimulation conditions
may specify distinct cellular outcomes based on recruitment of
differentially regulated effector molecules.
PIP3 AND PI(3,4)P2 BINDING PROTEINS
Phosphoinositides generated by active PI3Ks provide binding
sites for some signaling proteins containing PI-binding domains
such as PH domains (Dowler et al., 2000; Lemmon and Fergu-
son, 2000) and phox homology (PX) domains (Kanai et al., 2001;
Sato et al., 2001). Akt phosphorylation is often used as a read-
out of PI3K activity, as D3 phosphoinositides are required to
recruit Akt itself to the cell membrane along with its activator,
PDK (Burgering and Coffer, 1995; Anderson et al., 1998). The
PH domain of Akt binds to both PIP3 and PI(3,4)P2 (Frech et al.,
1997). While PI(3,4)P2 has been implicated in Akt phosphoryla-
tion and activation (Frech et al., 1997; Ma et al., 2008) some studies
suggest that PIP3 is the limiting factor for Akt membrane recruit-
ment and activation (Astoul et al., 1999). Notably, Akt activation
appears to be increased by selective deregulation of PIP3 via loss
of SHIP (Liu et al., 1998) or selective deregulation of PI(3,4)P2
by loss of INPP4 (Gewinner et al., 2009). Thus Akt phospho-
rylation may integrate to some extent both PIP3 and PI(3,4)P2
levels. Direct evidence for the function of Akt in BCR signaling
is scarce, however a recent study reported that combined deletion
of Akt1 and Akt2 in B cells affects B cell maturation and survival
(Calamito et al., 2010).
Another key process triggered by BCR-induced PIP3 produc-
tion is the formation of a “signalosome” involving the tyrosine
kinase Btk which contributes to PLCγ2 activation and Ca2+
ﬂux (O’Rourke et al., 1998; DeFranco, 2001; Engels et al., 2001;
Chiu et al., 2002). Btk contains a PH domain that binds to PIP3
with a high degree of selectively (Salim et al., 1996), and loss
of PIP3 binding leads to loss of Btk function (Rawlings et al.,
1993). BCR stimulation leads to a rapid, transient rise in PIP3
levels that temporally correlates with the membrane recruitment
of Btk (Marshall et al., 2002). Both PIP3 levels and Btk PH
recruitment can be inhibited by PI3K inhibition or by condi-
tions that promote SHIP activity (Krahn et al., 2004). Bypassing
PI3K-dependent recruitment of Btk by a membrane targeted Btk
construct overcomes the inhibitory effect of SHIP on Ca2+ ﬂux
(Bolland et al., 1998).
B cells also express a number of adaptor proteins and gua-
nine nucleotide exchange factors that contain PI-binding domains
with various degrees of selectivity for PI3K products. The PH
domain adaptor protein Bam32 is selectively expressed in immune
cells and has high afﬁnity and high selectivity for binding to
PIP3 and PI(3,4)P2, while TAPP adaptor proteins selectively bind
PI(3,4)P2 (reviewed in Zhang et al., 2009b). TAPP adaptors show
delayed and sustained membrane localization after BCR stim-
ulation which correlated well with the timing of the PIP3 to
PI(3,4)P2 conversion (Marshall et al., 2002; Krahn et al., 2004).
H2O2 induced selective recruitment of TAPP proteins in B cells
(Cheung et al., 2007). Membrane recruitment of TAPP1-PH is
signiﬁcantly impaired when PTEN is re-expressed in PTEN-null
B cells (Cheung et al., 2007) or when inositol 4′-phosphatase is
over-expressed in non-immune cells (Ivetac et al., 2009), sug-
gesting that PI(3,4)P2-dependent responses can be regulated by
both of these phosphatases. Given the differential control of PIP3
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and PI(3,4)P2 by phosphatases and the existence of distinct bind-
ing proteins, it seems likely that these phosphoinositides impact
different aspects of B cell activation.
ROLES OF THE PI3K PATHWAY IN NORMAL B CELL FUNCTION
B CELL DEVELOPMENT
B cell development and maintenance are dependent on “positive
selection” signals initiated by the pre-BCR and BCR and the PI3K
pathway has clearly been demonstrated to be a critical component
of these developmental and homeostatic signals. We will provide
only a brief overview of this area since excellent reviews covering
this in detail are available (Okkenhaug and Fruman, 2010).
Mutations targeting p85α or p110δ have been shown to retard
B cell maturation at the pro-B cell stage within the bone mar-
row and lead to a reduction in mature B cells within the spleen
and lymph nodes (Fruman et al., 1999; Suzuki et al., 1999; Clayton
et al., 2002; Jou et al., 2002; Okkenhaug et al., 2002). Disruption of
BCR-induced PI3K activation in CD19/BCAP double knock-out
mice also led to severe impairment in the generation of imma-
ture and mature B cell subsets within the spleen and bone marrow
(Aiba et al., 2008). In contrast, deletion of p110γ did not affect
B cell development; however it did have a profound impact on
thymocyte development and mature T cell activation (Sasaki et al.,
2000). It was found that combined deletion of p110δ and p110γ
impairs B cell development to a greater extent than p110δ deﬁ-
ciency alone, however it is not clear to what extent this reﬂects a
B cell-intrinsic requirement for p110γ (Beer-Hammer et al., 2010).
While deﬁciency in p110αdidnot affect B cell development orBCR
signaling, combined deletion of p110α and p110δ led to a nearly
complete block in B cell development (Ramadani et al., 2010).
This result suggests that p110α may make an important contribu-
tion to tonic pre-BCR and BCR signaling, but is less important
for signaling induced by acute BCR cross-linking. p110β appears
to be dispensable for both B cell development and activation
(Ramadani et al., 2010).
At the pro/pre-B cell transition, PI3K signaling appears to be
essential to turn off recombination-activating gene (RAG) expres-
sion to ensure allelic exclusion (Tze et al., 2005; Verkoczy et al.,
2007). RAG expression must again be down-regulated once B cells
reach the immature stage and this process has been shown to
speciﬁcally depend on p110δ (Llorian et al., 2007). The mech-
anism for PI3K regulation of RAG expression depends on Akt,
which phosphorylates and inactivates the transcription factor
FOXO1. FOXO1 is able to directly bind to RAG gene promot-
ers, facilitating the transcription of both RAG1 and RAG2; thus,
pre-BCR-dependent PI3K signaling turns off RAG expression by
inactivating FOXO1 (Amin and Schlissel, 2008). FOXO1 is how-
ever required for early B cell development, since FOXO1 deﬁciency
leads to impaired expression of IL-7Rα and RAG in pro-B cells
(Dengler et al., 2008). These results point to dual roles of PI3K
signaling in promoting and repressing different aspects of B cell
differentiation, which is also observed in late B cell differentiation
in germinal centers (GC; see below).
Studies in mice with SHIP deletion suggest that deregula-
tion of PIP3 levels can impact B cell maturation. SHIP-deﬁcient
mice had decreased numbers of pre- and immature B cells
but increased number of total B cells in the spleen. Further
study provided evidence for accelerated B cell development and
quicker emigration from the bone marrow in the deﬁcient cells,
implying that SHIP restrains developing B cells from moving
through immature and transitional stages to the mature stage
(Brauweiler et al., 2000).
INNATE-LIKE B CELL POPULATIONS
The PI3K signaling pathway appears particularly critical for gen-
eration and/or maintenance of innate-like B cell populations (B1
and marginal zone B cells). B1 and MZ populations are nearly
absent in p85- or p110δ-deﬁcient mice (Clayton et al., 2002;
Donahue et al., 2004). Subsequent studies found that B cell spe-
ciﬁc deletion of p110δ led to loss of both MZ and B1 B cells,
indicating an intrinsic requirement for PI3K in the development
of these cells (Rolf et al., 2010). In contrast, follicular B cells num-
bers are notmarkedly diminished in p110δdeﬁcientmice; however
dual loss of p110δ and CD19 does substantially reduce FO B cell
numbers (Kovesdi et al., 2010), suggesting other p110 isoforms
and/or other pathways activated by CD19 are sufﬁcient to main-
tain FO B cells in the absence of p110δ. p110δ mutant mice also
showed reduced natural antibodies and reduced T-independent
responses characteristic of innate-like B cell populations (Okken-
haug et al., 2002; Durand et al., 2009). Conversely, B1 and MZ
populations were increased in mice with B cell speciﬁc deletion
of PTEN (Anzelon et al., 2003). Combined deﬁciency of p110δ
and PTEN restored the B1 population to normal numbers, but
only partially reduced the MZ B cell population, suggesting that
additional PI3K isoforms may promote MZ B cell development
(Janas et al., 2008).
Interestingly, SHIP-deﬁcient mice show a defect in MZ B cell
development; however thiswas reported tobe secondary to adefect
in marginal zone macrophages rather than a B cell-intrinsic defect
(Karlsson et al., 2003). This suggests that increased PIP3 levels
may not be sufﬁcient for innate-like B cell expansion: deregula-
tion of both PIP3 and PI(3,4)P2 (i.e., PTEN deﬁciency) may be
required. The effect of B cell speciﬁc deletion of SHIP on innate-
like B cell development has not been reported to our knowledge.
Combined deﬁciency of Akt1 and Akt2 led to selective reduc-
tion in B1 and MZ populations (Calamito et al., 2010), indicating
that Akt is one of the PI3K effectors required for innate-like
B cell development. The FOXO1 transcription factor, which is
a direct target of Akt, is also implicated in MZ B cell development
(Chen et al., 2010).
Several studies indicate that the PI3K pathway is also involved
in both homeostatic maintenance and activation of innate-like
B cell subsets. Treatment of normal mice with the p110δ inhibitor
IC87114 leads to a striking depletion of MZ B cells from the
spleen (Durand et al., 2009), suggesting that continuous PI3K
tonic signals may be required to maintain the MZ compartment.
Consistent with this study, we have found that oral treatment with
IC87114 leads to signiﬁcant MZ B cell depletion within 4 days and
appears to be reversible upon discontinuation of treatment. Since
integrin blockade was also found to deplete MZ B cells from the
spleen (Lu and Cyster, 2002), it is possible that acute p110δ inhibi-
tion may impact on the MZ B cell compartment by antagonizing
the adhesive interactions of MZ B cell within this microenviron-
ment. This would seem to parallel the ﬁndings in B cell leukemia
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where acute p110δ inhibition leads to release of leukemic cells
from lymphoid tissues into circulation (see below). However more
work will be required to determine the contributions of B cell-
intrinsic de-adhesion versus indirect effects of p110δ inhibition
on the microenvironment and/or induction of apoptosis due to
loss of tonic BCR signaling.
p110δ mutation or pharmacological blockade inhibited the
ability of splenic B cells to produce IL-10 after stimulation with
TLR ligands (Dil and Marshall, 2009), consistent with ﬁndings
that marginal zone B cells are a major source of IL-10 and may
have a unique capacity to generate regulatory B cells (Lund,
2008). p110δ blockade also impairs TLR-induced proliferation
and chemokine-induced adhesion and migration responses of MZ
B cells in vitro (Durand et al., 2009). The latter ﬁndings contra-
dict the paradigm which suggests that only class 1B PI3Ks are
linked to G protein-coupled receptors such as chemokine recep-
tors; however they are consistent with ﬁndings in neutrophils
which clearly show that p110δ functions in migration responses
and respiratory burst triggered by GPCRs (Sadhu et al., 2003;
Condliffe et al., 2005).
ANTIGEN PRESENTATION
B cell Ag presentation involves a number of complex cell bio-
logical processes, including BCR–Ag endocytosis and intracellular
trafﬁcking, formation of specialized compartments for Ag degra-
dation and peptide loading onto MHC molecules, and formation
of stable cell–cell conjugates with Ag-binding T cells (Figure 2).
Several early studies using high doses of less speciﬁc PI3K
inhibitors found that PI3K activity was required for optimal B cell
Ag presentation function in vitro (Granboulan et al., 2003). Some
studies suggested PI3K-dependent signal are required at the level
of BCR endocytosis (Phee et al., 2001); however we and others
have found that BCR endocytosis of soluble Ag does not require
PI3K (Al-Alwan et al., 2007). Studies usingAgs tethered to artiﬁcial
membranes found that Ag uptake is associated with a cell spread-
ing and contraction response that requires p110δ PI3K, CD19,
Vav, and Rac (Arana et al., 2008; Depoil et al., 2008). These studies
suggest that physiological “Ag gathering” from cell surfaces likely
requires 3-phosphoinositide-dependent activationof RacGTPases
(Figure 2).
We found that pharmacological or genetic inactivation of p110δ
impairs BCR-mediated Ag presentation function, and this was
associated with a defect in generation of polarized conjugates
with cognate T cells (Al-Alwan et al., 2007). It remains to be
determined whether PI3K-dependant signals impact intracellu-
lar Ag trafﬁcking or generation of the MHCII peptide loading
compartment; however we found no effect of PI3K inhibitors on
generation of the MHCII–peptide complexes in a murine cell line.
On the other hand, p110δ is clearly required for efﬁcient B cell
adhesion mediated by LFA1–ICAM and chemokine-induced cell
spreading and migration (Durand et al., 2009). In contrast with
p110δ inhibition, p110δ deletion was not found to impair BCR-
mediated Ag presentation (Rolf et al., 2010). The reasons for this
discrepancy are unclear, but may reﬂect compensatory mecha-
nisms in the deletion model, or other differences in systems used
(e.g., different BCR expression/afﬁnity in transgenic versus non-
transgenic systems). The SLAM family receptor CD150, known to
FIGURE 2 | Role of the PI3K pathway in B cell antigen presentation
functions.The Figure outlines the D3 phosphoinositides and PI-dependant
signaling complexes implicated in cytoskeletal reorganization associated
with B cell Ag uptake and presentation. The involvement of different
components in different steps of Ag presentation is discussed in the text.
have a selective role in B:T cell adhesion (Cannons et al., 2010), was
shown to activate the PI3K pathway (Mikhalap et al., 2004), sug-
gesting another possible PI3K-dependant adhesion mechanism.
Together these studies suggest that PI3K signaling may primarily
impact B:T conjugate formation at the level of cell migration and
adhesion.
A few PI-binding proteins have been implicated in B cell
migration, adhesion, and cell:cell conjugate formation (Figure 2),
however the mechanisms remain incompletely understood. The
Rac-GEF Vav, which has a PIP3-binding PH domain, is important
in B cell spreading and contraction responses (Arana et al., 2008).
We found that the Bam32/DAPP1 adaptor promotes efﬁcient Rac
activation and B cell spreading on integrin ligands (Al-Alwan et al.,
2010). The activation of Rap GTPase, which is important for
cytoskeletal rearrangements occurring in B cell adhesion, spread-
ing, and migration responses (Lin et al., 2008), was found to be
dependent on p110δ (Durand et al., 2009).
While the relative importance of PIP3 and PI(3,4)P2 in B cell Ag
gathering and conjugate formation is not clear, SHIP appears to
play both positive and negative roles. SHIP-deﬁcient B cells show
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increased spreading responses and increased F-actin accumula-
tion, presumably due to increased Btk recruitment, but impaired
centripetal movement and growth of BCR clusters (Liu et al.,
2011). This study suggests that while PIP3 drives Btk-dependent
F-actin polymerization required for Ag-induced B cell spreading,
conversion to PI(3,4)P2 by SHIP may then promote “gathering”
of BCR–Ag microclusters into large aggregates for internaliza-
tion. In other cell systems, SHIP has been found to promote
certain cellular responses related to cytoskeletal dynamics (Nishio
et al., 2007; Severin et al., 2007; Harris et al., 2011). For exam-
ple, although knock-down of SHIP in primary human T cells
resulted in increased total F-actin, it also paradoxically led to loss
of actin-rich microvilli projections (Harris et al., 2011). Although
incompletely understood, recruitment of PI(3,4)P2-speciﬁc effec-
tors by SHIP such as TAPP2 (Dowler et al., 2000) and lamellipodin
(Krause et al., 2004) may be central to these and other positive
regulatory mechanisms.
CLASS SWITCH RECOMBINATION
We and others have found that PI3K regulates Ig class switch
recombination (CSR), with either pharmaceutical blockade or
genetic deﬁciencies in PI3K leading to markedly enhanced switch
to IgG1 or IgE isotypes (Omori et al., 2006; Zhang et al., 2008).
CSR, also known as isotype switching, is a speciﬁc DNA
recombination mechanism that replaces the currently expressed
immunoglobulin heavy chain constant region gene (CH) with
one downstream CH gene. Switch (S) regions are highly repeti-
tive sequences upstream of each CH gene which are regulated by
sterile germline transcripts (GLTs). Speciﬁc GLTs are induced by
cytokines and T cell-derived signals, such as IL-4Ra and CD40
(Stavnezer et al., 1988; Nambu et al., 2003). In addition, these sig-
nals induce the expression of the enzyme AID, which serves a
critical catalytic function for CSR.
Several lines of evidence indicate that PI3K signaling can
suppress CSR through Akt-dependant inactivation of FOXO tran-
scription factors which drive expression of AID (Figure 3). PI3K
blockade markedly increased expression of AID and this was
reversed by constitutively active Akt (Omori et al., 2006). More-
over, we found that inhibition of Akt activity is sufﬁcient to
deregulate AID expression (Zhang et al., 2012). Conversely PTEN
deﬁciency leads to reduced isotype switch associated with reduced
AID expression (Suzuki et al., 2003). Constitutively active FOXO1
activated AID transcription (Omori et al., 2006) while FOXO1-
deﬁcient B cells showed reduced AID expression (Dengler et al.,
2008), indicating that Akt regulates AID by inactivating FOXO.
While IL-4 is an important driver of CSR, mice with a targeted
mutation in the insulin receptor substrate-2 binding site of the
IL-4Ra chain, which impairs IL-4 induced PI3K activation, were
reported to paradoxically show increased CSR to the IgE isotype
(Blaeser et al., 2003). This suggests that PI3K activation via the
IL-4R may modulate CSR in vivo.
We found that PI3K blockade has a particularly potent effect
on CSR to the IgE isotype. Genetic or pharmaceutical inactiva-
tion of p110δ resulted in markedly increased IgE levels in vivo
despite reducedGC responses and reducedproduction of IL-4 byT
cells (Nashed et al., 2007; Zhang et al., 2008). Increased IgE switch
was associated with elevated epsilon GLTs (εGLTs) in addition
FIGURE 3 | Role of the PI3K pathway in Ig isotype switch.The ﬁgure
depicts the regulatory linkages through which PI3K impacts on Ig isotype
switch to IgG and IgE. PI3K-dependent activation of Akt leads to
phosphorylation and inactivation of FOXO transcription factors, which
drive expression of AID, an enzyme required for all isotype switch.
PI3K-dependent, Akt-independent enhancement of BCL6 expression
(through an unknown mechanism) promotes the GC B cell gene expression
program and also suppresses germline transcription of the IgE locus
(eGLT), selectively repressing switch to IgE.
to increased AID expression (Zhang et al., 2008). Production of
εGLTs is controlled by the promoter of Iε exon, which contains
binding sites for many transcription factors such as STAT6, BCL6,
NF-κB, PU.1, PAX5, AP1, and E-box binding sites (Oettgen and
Geha, 2001). All of these transcription factors promote the tran-
scription of εGLTs except BCL6, which is a negative regulator that
competes with STAT6 for promoter binding (Harris et al., 1999).
We recently found that blockade of p110δ PI3K decreases the
expression of BCL6, providing a potential mechanism for PI3K
regulation of IgE (Figure 3). Re-expression of BCL6 was sufﬁcient
to reverse excess εGLT expression and IgE switch (Zhang et al.,
2012). Interestingly, selective blockade of Akt markedly enhanced
AID expression as expected, but had no effect on BCL6 or εGLT
expression (Zhang et al., 2012), suggesting other PI3K-dependent
signals may regulate BCL6.
T CELL-DEPENDANT ANTIBODY RESPONSES
TheT cell-dependent (TD) antibody response and associatedB cell
selection in GC is a fascinating system for generation of high afﬁn-
ity isotype-switched antibodies as well as B cell memory. The PI3K
pathway acts at multiple levels to regulate these responses gener-
ated by follicular B cells. Inactivation of p85 or p110δ or treatment
with p110δ-selective PI3K inhibitors signiﬁcantly perturb func-
tional responses of follicular B cells in vitro, including reduced
BCR-induced proliferation, increased susceptibility to apoptosis,
and impaired adhesion and migration responses (Clayton et al.,
2002; Okkenhaug et al., 2002; Durand et al., 2009). It should be
noted that some responses are not decreased by p110δ blockade,
including proliferative responses induced by CD40 and isotype
switch as described above.
In vivo, p85 or p110δ mutant mice show dramatically reduced
antibody production after immunization with TD Ags (Suzuki
et al., 1999; Clayton et al., 2002; Okkenhaug et al., 2002; Okken-
haug and Vanhaesebroeck, 2003). Impairment of BCR-induced
PI3K activation by deletion or mutation of CD19 was also found
to signiﬁcantly impair GC differentiation and Ab responses to
TD Ags (Rickert et al., 1995). Dual inactivation of PTEN and
CD19 was found to restore the ability to mount GC responses
(Anzelon et al., 2003). Deletion of SHIP results in enhanced Ab
responses to TD Ags (Helgason et al., 2000). However SHIP dele-
tion affects many immune cell types resulting in severe systemic
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pathology (Helgason et al., 1998), and the impact of B cell speciﬁc
deletion of SHIP on TD responses has not been reported to our
knowledge.
Consistent with failure to induce TD Ab responses, many of
the above studies also found that p110δ deﬁciency virtually abro-
gates the generation of GC. Similarly we have found that treatment
with IC87114 strongly reduces GC responses, without the associ-
ated decreased serum Ig levels seen in p110δ mutant mice (Zhang
et al., 2008, 2012). We found that IC87114 treatment of mice with
a pre-established GC response signiﬁcantly reduced the number of
GC B cells, suggesting that continuous p110δ signaling is required
for GC maintenance since. As discussed above p110δ appears to
have an ancillary function in maintaining expression of BCL6,
a key transcriptional regulator for the GC B cell genetic pro-
gram, providing a potential mechanism linking p110δ to GC B cell
maintenance.
Given the substantial evidence for a B cell-intrinsic require-
ment for p110δ, it was surprising when Rolf et al. (2010) found
that B cell speciﬁc deletion of p110δ did not markedly impair
TD Ab or GC responses. This result may suggest that other PI3K
isoforms such as p110α can functionally compensate for loss of
p110δ in the context of the GC response. Since follicular B cell
responses to CD40 and TLR ligands seem to be less dependent
on the PI3K pathway, it is possible that, under immunization
conditions generating abundant T cell help and other adjuvant-
induced activation signals, the D3 phosphoinositide levels may
not be a limiting factor controlling GC size. Interestingly, Rolf
et al. (2010) also found compelling evidence that p110δ plays an
important role in follicular helper T cell (TFH) function. Thus,
the dramatic loss of GC responses associated with p110δ block-
ade is likely due to the combined impact on GC B cells and
TFH cells.
Accumulating evidence indicates that selection of high afﬁnity
B cell clones within the GC is driven largely by cognate interac-
tions with TFH, which deliver co-stimulatory signals required for
continued GC B cell survival (King et al., 2008). Given the evi-
dence outlined above regarding the roles of the PI3K pathway in
B cell migration, adhesion and Ag presentation to T cells, PI3K
signaling would be expected to have an important role in afﬁnity
maturation. However, there is currently limited evidence sup-
porting this proposition. As noted above, p110δ-deﬁcient B cells
show only subtle reductions in afﬁnity maturation (Rolf et al.,
2010) while p110α/δ double deﬁciency abrogates B cell devel-
opment (Ramadani et al., 2010), precluding afﬁnity maturation
studies.
We found that the PI-binding adaptor protein Bam32/DAPP1 is
required for optimal B cell Ag presentation, and Bam32-deﬁcient
mice showed premature dissolution of the GC response and
impaired afﬁnity maturation (Zhang et al., 2010b). It should be
noted that the GC defect in Bam32-deﬁcient mice was observed
under conditions of relatively low precursor frequency of Ag-
speciﬁc B and T cells (i.e., no Ag receptor transgenes) and with
relative mild adjuvant conditions (OVA/alum). Bam32-deﬁcient
mice were able to generate relatively normal GC responses after
immunization with sheep red blood cells, known to activate
large numbers of lymphocytes and to contain a potent adju-
vant (hemin). It is tempting to speculate that, under conditions
of limiting T cell numbers in GC, BCR-induced activation of
PI3K may recruit PI-binding proteins such as Bam32 and Vav
to the plasma membrane and provide a selective advantage to GC
B cells by enhancing their ability to form cognate interactions.
In this context it would be interesting to examine the ability of
p110δ-deﬁcient B cells to compete with wild-type B cells within a
GC response.
CONTROL OF B CELL HOMEOSTASIS AND ANERGY
Three studies performed in mice harboring B cell-targeted dele-
tions of PTEN have shed light on the speciﬁc roles of this
phosphatase in B cell homeostasis (Anzelon et al., 2003; Suzuki
et al., 2003; Browne et al., 2009). Both immature and mature
PTEN-deﬁcient B cells exhibited hyper-activation and hyper-
proliferation in response to various stimuli (Anzelon et al., 2003;
Suzuki et al., 2003; Browne et al., 2009). Mature B cell populations
also displayed enhanced migration and resistance to apoptotic sig-
nals (Suzuki et al., 2003). Two of the studies report an increase
in autoantibody titer (Suzuki et al., 2003; Browne et al., 2009),
which one study attributed to abnormal generation of innate-
like B cells (Suzuki et al., 2003). In the context of chronic self-Ag
stimulation, anergic BCR transgenic B cells showed increased
expression of PTEN and showed reduced PIP3 levels after BCR
cross-linking, suggesting that dampening of the PI3K pathway
via PTEN may be a signiﬁcant component of anergy induction
(Browne et al., 2009). Consistent with this idea, PTEN-deﬁcient
BCR transgenic cells failed to develop anergy in presence of self-
Ag (Browne et al., 2009). Notably, PTEN can also act as a protein
phosphatase (Myers et al., 1997). The extent to which the effect
of PTEN on B cell anergy is due its PI-hydrolyzing function is
unclear, and the relative contributions of innate-like B cell popu-
lations andGCdefects to autoimmunity development remain to be
determined.
Deregulation of PI dynamics via deletion of SHIP has also been
reported to impact B cell anergy. SHIP-deﬁcient B cells were shown
to exhibit heightened in vitro responsiveness, including increased
phosphorylation of Akt and MAPKs as well as enhanced prolifer-
ation, survival and cell cycling upon stimulation through the BCR
(Helgason et al., 2000). SHIP−/− mice also display elevated serum
Ig levels and increased Ag-speciﬁc IgG in response to a T cell-
independent Ag (Helgason et al., 2000). Another group found that
SHIP-deﬁcient B cells were more sensitive to induction of CD86
expression upon BCR ligation and more sensitive to BCR-induced
apoptosis (Brauweiler et al., 2000). Recently, B cell-targeted SHIP-
deﬁcient mice were characterized (O’Neill et al., 2011). These mice
displayed a severe lupus-like autoimmune phenotype featuring
increased autoantibodies produced against nuclear components
and IgG deposition in glomeruli of the kidneys. The authors also
showed that SHIP phosphorylation is increased in primary anergic
B cells from wild-type mice, suggesting that increased SHIP activ-
ity may contribute to low PIP3 levels. The authors hypothesize
that chronic monophosphorylation of Igα/β (CD79a/b) ITAMs by
Src family kinases in anergic B cells leads to constitutive activation
of SHIP, which is essential for the maintenance of B cell anergy
(O’Neill et al., 2011).
We have recently completed a study on mice bearing mutations
in the PH domains of TAPP1 and TAPP2 (Landego et al., 2012).
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These mutations effectively uncouple TAPP adaptors from the
SHIP product PI(3,4)P2 (Wullschleger et al., 2011). It was
found that TAPP mutant B cells display exaggerated prolifera-
tive responses to BCR cross-linking which was associated with
increased Akt phosphorylation. Strikingly these mice show several
additional similarities to SHIP-deﬁcient mice, including increased
basal Ig levels, autoantibodies and development of lupus-like
disease. Given the similar phenotypes observed in TAPP KI
and SHIP-deﬁcient mice, it is tempting to speculate that TAPP-
PI(3,4)P2 interactions may in part mediate the regulatory effects
of SHIP in B cells. The mechanism by which TAPPs antagonize
Akt activity is currently unclear, but may involve competition for
PI(3,4)P2 or recruitment of a regulatory phosphatase.
Consistent with the reported role of PIP3 phosphatases in
maintaining anergy, haploinsufﬁciency of PI3K p110δ was very
recently reported to partially attenuate the autoimmune pheno-
type of Lyn-deﬁcient mice (Maxwell et al., 2012). Plasma cell
numbers were reduced, as were titers of antibodies and autoan-
tibodies in the serum. The hyper-proliferative B cell phenotype
was also moderated. Lyn−/−p110δ+/KD B cells maintained high
basal and BCR-stimulatedAkt and MAPK phosphorylation as well
as increased surface expression of CD80 and CD86 characteris-
tic of Lyn-deﬁcient B cells. Since myeloid cells and T cells likely
contribute to the reduction of disease severity (Maxwell et al.,
2012), the contribution of B cell-intrinsic p110δ signaling in this
autoimmune mouse model is not yet clearly deﬁned.
MECHANISMS OF PI3K ACTIVATION IN MALIGNANT B CELLS
The ﬁnding that BCR signaling via PI3K is critical for mature
B cell homeostasis and function has driven interest in understand-
ing the role of the PI3K pathway in malignant B cells. The PIK3CA
gene is mutated in many cancers but rarely in hematological dis-
orders, as a recent study on multiple myeloma (MM) conﬁrmed
(Ismail et al., 2010). Together with the ﬁnding that PTEN muta-
tions are relatively rare in B cell malignancies (Leupin et al., 2003;
Georgakis et al., 2006), the initial conclusion was that PI3K sig-
naling was less critical in these diseases compared to solid tumors.
However, constitutive PI3K activity is signiﬁcantly increased in
chronic lymphocytic leukemia (CLL) relative to normal B cells
(Herman et al., 2010; Ringshausen et al., 2002). Enhanced basal
and stimulated Akt phosphorylation is observed in a subset of
CLL patients, with increased phosphorylation associatedwith pro-
gressive disease (Barragan et al., 2006; Longo et al., 2007) and
decreased phosphorylation associated with an “anergic” pheno-
type (Muzio et al., 2008). p110δ was reported to be marginally
over-expressed in CLL B cells (B-CLL) compared to normal B cells
(Herman et al., 2010), and as discussed below, recent results indi-
cate that this isoform is functionally important for Akt activation
and survival of malignant B cells. Current ﬁndings collectively
indicate that elevated PI3K pathway activity in B cell malignan-
cies is driven by altered BCR signaling (Figure 4) together with
other co-stimulatory signals present in lymphoid tissues such as
chemokines and cytokines. Below we review recent studies that
identify molecular alterations in malignant B cells affecting the
PI3K signaling pathway.We focus particularly onCLL,where there
is the most information available and promising clinical results of
PI3K inhibitors have been reported in early trials.
FIGURE 4 | Alterations in the PI3K pathway in malignant B cells.
In malignant B cells, several pathway players have been found to be
over-expressed or hyper-phosphorylated. The ﬁgure illustrates signaling
molecules whose expression, phosphorylation or activity are reported to be
altered in malignant B cells (green indicates increased activity, red indicates
reduced activity). Altered molecules discussed in the text include p110
subunits, Lyn, Syk, Btk, Akt, TC21, and the BCR signaling chain CD79b.
The formation of a non-physiological complex between Lyn and Hsp90 in
malignant B cells is indicated. Increased expression of microRNA species
that target PTEN and SHIP are reported to reduce expression of these
phosphatases. Moreover, the PTEN kinase CK2 is reported to be
over-expressed which may diminish PTEN activity. ZAP-70 is expressed in
some B cell malignancies, however the impact on the PI3K pathway is
currently not clear.
BCR AND ASSOCIATED PROTEIN TYROSINE KINASES
Many B cell malignancies show evidence of altered BCR signaling
(Figure 4), which is likely relevant to increased cell survival and
accumulation in blood and tissues. Compared to normal B cells,
B-CLL exhibit low surface expression of Ig and CD79b, associated
with low levels of mRNA encoding for CD79b (Thompson et al.,
1997). CD79b mRNA level was however found to be higher in the
more severe CLL prognostic group associated with unmutated Ig
heavy chain variable (VH) genes (Cajiao et al., 2007), suggesting
a possible link between CD79b expression and disease severity.
Some authors have compared this BCR-low phenotype to “aner-
gic”B cells which, in animal models, down-modulate surface BCR
in response to chronic BCR stimulation by low afﬁnity or solu-
ble self-Ags. Despite low BCR expression, B-CLL show evidence
of constitutively elevated PI3K pathway activity that is depen-
dent on protein kinases normally activated by the BCR, including
Lyn and Syk.
Lyn is over-expressed in CLL (Contri et al., 2005; Trentin et al.,
2008) and Hodgkin lymphoma (HL; Martin et al., 2011) and is
anomalously present in the cytosol where it forms an aberrant
complex with Hsp90 (Contri et al., 2005; Trentin et al., 2008).
In contrast with normal B cells, Lyn’s activity does not appear
to change with anti-IgM stimulation; however Lyn inhibition
induced apoptosis in CLL (Contri et al., 2005). Although no Syk
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mutations were found in CLL (Brown et al., 2008; Philippen et al.,
2010), Syk was found to be over-expressed at the protein level
(Buchner et al., 2009). In HL, Syk expression was associated with
shorter failure-free survival (Martin et al., 2011), while in plasma
cell-like Waldenström’s macroglobulinemia, BLNK and Syk genes
were reported to be up-regulated (Gutierrez et al., 2007). Consti-
tutive phosphorylation and activation of Syk has been observed
in acute lymphocytic leukemia (ALL), follicular lymphoma (FL),
diffuse large B cell lymphoma (DLBCL), and CLL, as reviewed
elsewhere (Efremov and Laurenti, 2011). The mechanisms under-
lying aberrant expression and activity of these kinases remain
unknown.
A subset of B-CLL can also express the Syk-family kinase ZAP-
70,which has been proposed to inﬂuence BCR signaling. Although
its role in leukemic B cells is not fully understood, ZAP-70 expres-
sion is used as a clinical marker predictive of aggressive clinical
course (Crespo et al., 2003; Orchard et al., 2004; Rassenti et al.,
2004). While ZAP-70 activation through the BCR is inefﬁcient
in CLL and lymphoma cell lines and appears to be negligible
compared to Syk activation, ZAP-70 can still recruit downstream
signaling molecules following BCR stimulation (Gobessi et al.,
2007). B cells from ZAP-70 positive CLL patients expressed more
phosphorylated Syk, PLCγ, and BLNK than ZAP-70 negative
B cells only after anti-IgM stimulation (Chen et al., 2005). Intro-
duction of ZAP-70 into ZAP-70 negative B cells also enhanced
Akt phosphorylation (Gobessi et al., 2007), suggesting the effects
on tyrosine kinase activation can leads to elevated PI3K activ-
ity. In transducing B-CLL with intact or mutant ZAP-70, Chen
et al. (2008) identiﬁed ZAP-70 SH2 domain but not its kinase
activity as necessary to induce calcium ﬂux after BCR stimula-
tion, suggesting that ZAP-70 can function as an adaptor protein
in BCR signaling. Interestingly, ZAP-70 expression was reported
to both prolong Syk activation and delay BCR internalization
(Gobessi et al., 2007; Calpe et al., 2011), suggesting that it
could help reduce BCR down-modulation in response to chronic
stimulation by self-Ags.
Besides altered protein tyrosine kinase activity, other mech-
anisms potentially affecting PI3K pathway activity in malignant
B cells have been proposed. The GTPase TC21, which promotes
PI3K activity presumably by recruiting p110δ to the BCR, is over-
expressed inDLBCLandHLcompared tohealthydonors (Delgado
et al., 2009), providing another potential gain-of-function mecha-
nism. Notably, the relative importance of classical modes of PI3K
recruitment downstream of BCR signaling, such as through CD19
or BCAP binding, versus other mechanisms such as TC21- or
insulin receptor substrate-dependent recruitment, is unknown
in malignant B cells. The adaptor p66Shc, which can inhibit
Akt phosphorylation and promote apoptotic signaling via the
BCR (Pacini et al., 2004), was profoundly impaired in B-CLL
compared to normal B cells, with lower expression in the unfavor-
able prognosis group (Capitani et al., 2010). The protein tyrosine
phosphatase receptor-type O (PTPRO) has been implicated as a
signiﬁcant regulator of protein tyrosine kinase activity in B cell
malignancy. Following the identiﬁcation of Syk as a target for
the truncated form of PTPRO (PTPROt) in a BCR stimulation-
independent manner (Chen et al., 2006), ZAP-70 and Lyn activ-
ities were shown to be inhibited by PTPROt in leukemic cells
(Motiwala et al., 2010). In CLL, extensive methylation of the CpG
island in the gene encoding PTPROt was detected in 82% of
patients (Motiwala et al., 2007). These ﬁndings suggest that Lyn,
Syk, and ZAP-70 hyper-activity could be due in part to epigenetic
silencing of their negative regulator and that this system regulates
tonic signaling from BCR.
PI PHOSPHATASES
Although PTEN is frequently mutated in several kinds of cancers,
it is rarely mutated in B cell malignancies (Leupin et al., 2003;
Georgakis et al., 2006). PTEN mutations were found in 5% of pri-
mary lymphomas (Gronbaek et al., 1998; Sakai et al., 1998) and
in two primary effusion lymphoma cell lines but not in primary
cells (Boulanger et al., 2009). However PTEN expression and func-
tion are regulated at transcriptional and post-transcriptional levels
via microRNAs, phosphorylation, ubiquitination and oxidation,
and substantial evidence now indicates that malignant B cells fre-
quently alter PTEN protein expression and function through such
mechanisms.
Several studies showed a reduction or loss of PTEN expres-
sion in DLBCL (Abubaker et al., 2007; Liu et al., 2010) and CLL
(Leupin et al., 2003). We found that the BJAB B cell lymphoma
has no detectable PTEN protein and highly elevated generation
of PIP3 and PI(3,4)P2 (Marshall et al., 2002; Cheung et al., 2007),
however PTEN mRNA appeared to be expressed normally in these
cells and contained no mutations. The miR-17-92 has emerged
as an important negative regulator of PTEN expression. This
microRNA cluster is over-expressed in several leukemias and lym-
phomas (Lenz et al., 2008; Rao et al., 2011) providing a potential
mechanism for PTEN down-regulation. Signaling via NOTCH1 is
reported to activate the PI3K pathway by inhibiting PTEN tran-
scription (Palomero et al., 2007) and NOTCH1 was recently found
to be mutated in CLL (Rosati et al., 2009; Fabbri et al., 2011; Balatti
et al., 2012; Rossi et al., 2012) and is a predictor of survival (Rosati
et al., 2009; Del Giudice et al., 2012; Rossi et al., 2012). More-
over, PTEN enzymatic activity is reported to be deﬁcient in CLL
(Shehata et al., 2010), suggesting that PTENpost-translational reg-
ulation is also altered in hematological cancer. In HL cell lines,
reduced PTEN function was suggested to be due to its phosphory-
lated status (Georgakis et al., 2006). A well-known PTEN regulator
CK2 is over-expressed and hyper-activated in CLL and CK2 block-
ade decreased PTEN phosphorylation, restoring PTEN activity
(Shehata et al., 2010; Martins et al., 2011).
Since SHIP is also an important regulator of PI3K signaling,
one might expect it to have tumor suppressor properties in the
immune cells. Indeed, this has been demonstrated for some hema-
tological malignancies (Fukuda et al., 2005; Vanderwinden et al.,
2006). Recent evidence, including data from human samples as
well as mouse models and tumor cell lines, supports a tumor
suppressor role in certain B cell malignancies as well. SHIP was
identiﬁed as a target of miR-155 (Costinean et al., 2009; Pedersen
et al., 2009), which is over-expressed in several B cell lymphomas
(Eis et al., 2005; Kluiver et al., 2005). One group studying DLBCL
found that the more aggressive disease type (non-GC DLBCL)
was associated with higher levels of miR-155, and consequently
lower levels of SHIP, compared to GC DLBCL. Patients with
the least SHIP expression also had the worst survival outcome
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(Pedersen et al., 2009). Another group independently conﬁrmed
that SHIP is often down-regulated in DLBCL patients (Miletic
et al., 2010). Interestingly, SHIP down-regulation occurs more fre-
quently in patients that have also down-regulated PTEN (Miletic
et al., 2010). Moreover, B cells from ZAP-70 positive CLL patients
exhibited decreased expression of SHIP as well as decreased SHIP
phosphorylation both basally and induced by BCR cross-linking
(Gabelloni et al., 2008).
Animal models support a role for SHIP as a tumor suppres-
sor in B cells. Transgenic mice overexpressing miR-155 develop
a mixed tumor phenotype with characteristics of ALL and high
grade lymphoma (Costinean et al., 2006). Further study revealed
that the highest miR-155 transgene expression in these mice
occurred in the bone marrow and, speciﬁcally, in pre-B cells.
The authors identiﬁed SHIP as one of the miR-155 targets which
showed decreased expression in pre-B lymphocytes and declined
further during progression to leukemia. Another mouse model
highlighting a protective role for SHIP in B cell cancers is a B cell-
speciﬁc double knock-out of PTENand SHIP (Miletic et al., 2010).
The authors found that unlike with B cell-speciﬁc deletion of
either phosphatase, lethal B cell neoplasms arose spontaneously
in double-deﬁcient mice. Since SHIP deletion is sufﬁcient to sub-
stantially deregulate PIP3 levels in B cells, its seems likely that
additional functions of PTEN, such as regulation of PI(3,4)P2 or
protein phosphatase activity may be required to poise B cells for
proliferative expansion.
Several studies have explored the impact of small molecule ago-
nists or antagonists of SHIP in B cell malignancies. When MM cell
lines were treated with a speciﬁc allosteric activator of SHIP,AQX-
MN100 (Ong et al., 2007), cell viability was signiﬁcantly reduced,
at least in part due to induction of apoptosis (Kennah et al., 2009).
Surprisingly, another group provide evidence that treatment with
compounds designed to inhibit rather than activate SHIP reduced
tonic and agonist-induced Akt activation and decreased viability
of blood cancer cells, including human MM cell lines (Brooks
et al., 2010). The authors suggest that these effects reﬂect that Akt
requires PI(3,4)P2 in addition to PIP3 for full activation (Scheid
et al., 2002). This study also provided some in vivo evidence
of the therapeutic potential of SHIP inhibition using a tumor
xenograft model. Interestingly, mice that were resistant to treat-
ment were found to have up-regulated SHIP2 in their tumor cells
(Fuhler et al., 2012).
The suggestion that both activation and inhibition of SHIP in
MM cells have potential therapeutic beneﬁts is puzzling. Certainly
the use of different cell lines is a major limitation in determin-
ing the relevance of these studies, and off-target effects of these
compounds cannot be ruled out. It is conceivable, however, that
both activation and inhibition of SHIP could independently lead
to apoptosis by different mechanisms. For example, activation
of SHIP leads to reduction of PIP3 which helps dampens effector
functions including cell proliferation, thus limiting tumor growth.
On the other hand, SHIP inhibition could reduce PI(3,4)P2
levels, affecting Akt activation or impacting other PI(3,4)P2-
binding proteins such as the TAPP proteins. It is also possible
that SHIP inhibition leads to chronically elevated PIP3 levels
which could trigger activation-induced cell death. Future stud-
ies in primary human MM cells will hopefully shed light on which
approach has the most therapeutic potential and in what disease
context.
PI3K PATHWAY INHIBITION AS A THERAPEUTIC STRATEGY
FOR B CELL MALIGNANCIES
As described above, the PI3K pathway plays pivotal roles in B cell
responses such as survival, activation, proliferation, cytoskeleton
dynamics, migration, and adhesion. Since the PI3K pathway is
deregulated at multiple levels in malignancies, this has become
a major target for new therapies. In fact, as PI3K inhibitors enter
clinical trials, some of the ﬁrst success stories have come fromB cell
malignancies. Given that PI3K enzymes do not act as a classical
mutated oncogene in these diseases, this early success has come
as somewhat of a surprise to many in the ﬁeld. In this section
we will focus on clinical results in CLL, which have taught us
much about therapeutic considerations and mechanisms of PI3K
inhibitors.
IN VITRO PI3K INHIBITOR STUDIES
The PI3K inhibitors LY294002 and wortmannin have both been
shown to have activity against CLL in vitro. LY294002 helped
to identify the PI3K pathway as the major pathway responsible
for IL-4 and plasma albumin-induced protection from apop-
tosis (Wickremasinghe et al., 2001; Barragan et al., 2002; Jones
et al., 2003). Phorbol 12-myristate 13-acetate (PMA)-induced Akt
activation is relatively insensitive to LY294002 (Barragan et al.,
2006). This PI3K inhibitor was suggested to induce B-CLL apop-
tosis by reducing X-linked inhibitor of apoptosis protein (XIAP)
expression (Ringshausen et al., 2002), caspase 8 cleavage (Plate,
2004), and Mcl-1 expression (Ringshausen et al., 2002; Spag-
nuolo et al., 2011). Wortmannin was found to inhibit B-CLL
migration to stromal cells mediated by CXCR4–CXCL12 (Burger
et al., 1999) and CXCR5–CXCL13 (Burkle et al., 2007). More-
over, LY294002 treatment enhanced B-CLL apoptosis induced by
Fludarabine (DNA synthesis inhibitor) or Dexamethasone (cor-
ticosteroid; Barragan et al., 2002), identifying the PI3K pathway
as a good candidate for combination drug therapy. LY294002
and wortmannin failed to enter clinical trials: LY294002 because
of dermal toxicity and low bioavailability (Hu et al., 2000);
wortmannin, due to liver and hematologic toxicity as well as
instability of the molecule (Ihle et al., 2004). Both of these com-
pounds have also been found to have signiﬁcant off-target effects
(Knight et al., 2006).
Recent drug development efforts have focused on generat-
ing compounds with improved speciﬁcity and bioavailability, as
well as targeting speciﬁc PI3K catalytic subunits (Marone et al.,
2008). Two more recently developed inhibitors, PI-103 and PIK-
90, are deﬁned as p110α multi-target inhibitors (Knight et al.,
2006), meaning they behave as pan-PI3K pathway inhibitors at
high doses (Raynaud et al., 2007) but can be used as p110α-speciﬁc
inhibitors at low doses (Niedermeier et al., 2009). Our group used
PI-103 to study the role of the PI3K pathway in B-CLL adhe-
sion to stromal cells, previously shown to provide efﬁcient B-CLL
protection (Kurtova et al., 2009). We observed that PI-103 abro-
gated B-CLL binding to stromal cells and inhibited B cell survival.
PI3K inhibition blocked adhesion of both ZAP-70 positive and
ZAP-70 negative B-CLL and reversed enhanced adhesion induced
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by CD40L + IL-4, IL-6, or IL-8 (Lafarge et al., in preparation).
Moreover, PI3K multi-target inhibitors were found to inhibit
B-CLL migration toward stromal cells via CXCL12, as well as
inhibit Akt and S6 phosphorylation more efﬁciently than speciﬁc
p110δ (IC87114) and p110β/δ (TGX115) inhibitors (Niedermeier
et al., 2009). These drugs also reversed stromal cell protection
and enhanced Fludarabine-induced apoptosis (Niedermeier et al.,
2009). These results indicate that PI3K inhibition is a promising
strategy to reverse B-CLL protection from apoptosis mediated by
stromal cell interactions.
Recent studies also indicate that speciﬁc inhibitors of p110δ
can have activity against CLL in vitro. CAL-101/GS-1101 is a
potent, orally bioavailable PI3K inhibitor highly selective for
the p110δ isoform. It has been shown to have activity against
multiple B cell malignancies (Lannutti et al., 2011). In vitro, CAL-
101 reduced B-CLL survival, associated with inhibition of Akt
(Herman et al., 2010; Hoellenriegel et al., 2011) and ERK (Hoel-
lenriegel et al., 2011) pathways, more efﬁciently than LY294002
(Herman et al., 2010). CAL-101 was also shown to induce B-
CLL apoptosis despite addition of protective factors such as
CD40L, BAFF, TNF-α, anti-IgM, ﬁbronectin, nurse-like cells
(NLC) co-culture, or stromal cells. Notably, CAL-101 did not
affect IL-4-induced survival (Herman et al., 2010; Hoellenriegel
et al., 2011), suggesting that IL-4 in this context signals survival
through another pathway or another PI3K isoform. In addition to
CLL, recent studies suggest CAL-101 may have therapeutic activity
in MM (Ikeda et al., 2010) and HL cells (Meadows et al., 2012).
In B-CLL co-cultures with NLC, CAL-101 inhibited the pro-
duction of many cytokines and chemokines (CCL7, CCL17,
CCL22, CXCL13, CD40L, and TNF-α). Interestingly, IL-6 levels
were unaltered following CAL-101 treatment in this co-culture
system (Hoellenriegel et al., 2011), implying that production of
this cytokine alone was p110δ-independent. Moreover, CAL-
101 inhibited B-CLL migration toward CXCL12, CXCL13, and
stromal cell lines (Hoellenriegel et al., 2011). In normal cells,
CAL-101 showed low toxicity for T and NK cells, but signiﬁ-
cantly reduced production of IFN-γ by NK cells and production
of several T cell cytokines (IL-6, IL-10, TNF-α, and CD40L
mRNA). Consistent with this ﬁnding, we have found that the
p110δ inhibitor IC87114 markedly inhibits cytokine production
by human T cells, while inducing minimal apoptosis (Lotoski
et al., submitted). The production of these protective cytokines
was also reduced in NK and T cells from CLL patients (Herman
et al., 2010). Lastly, CAL-101 enhanced the cytotoxic activity of
Fludarabine, Dexamethasone, and Bendamustine (DNA synthe-
sis inhibitor; Hoellenriegel et al., 2011). Together these results
suggest that p110δ inhibition has potential to selectively block
both intrinsic (BCR tonic) and extrinsic signals from the lym-
phoid tissue microenvironment promoting B-CLL survival and
proliferation.
EARLY CLINICAL TRIAL RESULTS
Early clinical trial results have revealed potential efﬁcacy as well as
insights into the in vivo mechanisms of action of p110δ inhibitors.
After 28 days of CAL-101 treatment, plasma from CLL patients
showed lower levels of CCL3/4 (Hoellenriegel et al., 2011) and
CXCL13 (Brown et al., 2011; Hoellenriegel et al., 2011) and B-CLL
from these patients showed lower levels of Akt phosphoryla-
tion (Brown et al., 2011; Hoellenriegel et al., 2011). Strikingly,
these patients presented with increased numbers of B-CLL in the
peripheral blood (absolute lymphocyte count, ALC), presumably
reﬂecting release of the malignant cells from lymphoid tissues
(Hoellenriegel et al., 2011). Patients treatedwithCAL-101plusRit-
uximab or Bendamustine did not increase their ALC, potentially
reﬂecting more efﬁcient killing of B-CLL after release from protec-
tive tissue microenvironments (Castillo et al., 2012). Brown et al.
(2011) reported marked lymph node shrinkage and found that
ALC increased shortly after treatment with either CAL-101 alone
or combination therapies. With CAL-101 alone, ALC stayed high
for an extended period, whereas with CAL-101 plus Bendamustine
ALC rapidly decreased over time.
Together, current data suggests that p110δ inhibition releases
B-CLL from their protective microenvironment but does not
by itself efﬁciently induce their apoptosis in vivo. Since CLL
is characterized by the progressive accumulation of B-CLL in
the peripheral blood, lymph nodes, spleen, and bone marrow
(Cheson et al., 1996; Hallek et al., 2008), and these microenvi-
ronments play a major role in providing survival signals from
supporting cells, this “tissue release” action seems likely to provide
clinical beneﬁt. This ﬁnding was somewhat unexpected, how-
ever it is consistent with accumulating data from in vitro models
showing that PI3K inhibitors can disrupt B-CLL-stromal interac-
tions and with mouse models showing that p110δ inhibition can
release marginal zone B cells from the spleen. Mechanistically, it is
currently unclear whether CAL-101 acts by directly antagonizing
B-CLL intrinsic chemotactic/adhesion responses required for tis-
sue retention or by altering production of chemotactic/adhesive
factors produced within other lymphoid tissue cells. Clinical
trials with CAL-101 and other PI3K inhibitors are on-going
and have expanded to other B cell malignancies including MM,
NHL, FL, HL, small lymphocytic lymphoma, and acute myeloid
lymphoma.
An interesting analogy was observed between CAL-101 and the
Btk inhibitor PCI-32765 (Ibrutinib). Brieﬂy, this Btk inhibitor
induced apoptosis in B-CLL but not in normal cells (Herman
et al., 2011) and reversed the microenvironment-induced sur-
vival (Herman et al., 2011), signaling (Herman et al., 2011; de
Rooij et al., 2012), adhesion (de Rooij et al., 2012), and migration
(Herman et al., 2011; Ponader et al., 2012). Moreover, in an adop-
tive transfer TCL1 mouse model of CLL, PCI-32765 was shown to
slow decrease progression (Chen et al., 2011; Ponader et al., 2012).
In early clinical trials, reduced lymph node size and increased
ALC were observed in almost all patients, as reviewed in (Ma and
Rosen, 2011). It seems that inhibiting p110δ or Btk have similar
outcomes: releasing B-CLL from their protective niche, leading to
clinical improvement.
CONCLUDING REMARKS
Studies of PI3Ks and the phosphatases that regulate their prod-
ucts have revealed the complex system of checks and balances
that control phosphoinositide accumulation. Clearly B cells can
integrate multiple signaling inputs to control the pathway appro-
priately under various biological circumstances. Interpretation of
the literature is complicatedby the fact thatmost functional studies
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looking at the roles of PI3K, PTEN,or SHIP do not include PI lipid
measurements. Given the discovery of various PI phosphatase-
independent functions of PTEN and SHIP, further work is needed
to verify conclusions about the roles of different PI species in B cell
biology. Of particular interest for the future is understanding the
signaling mechanisms linked to is the independently regulated
PI(3,4)P2 and their roles in normal andmalignant B cell functions.
The emerging importance PI3K pathway in B cell malignan-
cies seems to derive not from not from classical oncogenic or
tumor suppressor mutations, but from more subtle re-wiring of
the BCR-linked activation mechanisms present in normal B cells.
Thus, understanding the regulation and functions of the pathway
in normal B cells will continue to inform studies in B cell malig-
nancy as clinical applications move forward. Despite a signiﬁcant
literature on aberrant PI3K signaling in malignancy, the impact
of these changes on PI lipid dynamics remains largely unstudied,
representing a major gap in our understanding. Finally, as clinical
results have highlighted the importance of external inﬂuences on
thePI3Kpathway such as factors in the lymphoid tissuemicroenvi-
ronment, the contribution of this pathway in cell:cell interactions
inﬂuencing normal and malignant B cell biology is an important
area for future study.
REFERENCES
Abubaker, J., Bavi, P. P., Al-Harbi,
S., Siraj, A. K., Al-Dayel, F.,
Uddin, S., and Al-Kuraya, K. (2007).
PIK3CA mutations are mutually
exclusive with PTEN loss in diffuse
large B-cell lymphoma. Leukemia 21,
2368–2370.
Ackermann, J. A., Radtke, D., Mau-
rberger, A., Winkler, T. H., and
Nitschke, L. (2011). Grb2 regu-
lates B-cell maturation, B-cell mem-
ory responses and inhibits B-cell
Ca2+ signalling. EMBO J. 30, 1621–
1633.
Aiba, Y., Kameyama, M., Yamazaki,
T., Tedder, T. F., and Kurosaki, T.
(2008). Regulation of B-cell develop-
ment by BCAP and CD19 through
their binding to phosphoinositide 3-
kinase. Blood 111, 1497–1503.
Al-Alwan, M., Hou, S., Zhang,
T., and Marshall, A. J. (2010).
Bam32/DAPP1 promotes B cell adhe-
sion and formation of polarized con-
jugates with T cells. J. Immunol. 184,
6961–6969.
Al-Alwan, M. M., Okkenhaug, K.,
Vanhaesebroeck, B., Hayﬂick, J.
S., and Marshall, A. J. (2007).
Requirement for phosphoinositide 3-
kinase p110delta signaling in B cell
antigen receptor-mediated antigen
presentation. J. Immunol. 178,
2328–2335.
Al-Khouri, A. M., Ma, Y., Togo, S. H.,
Williams, S., and Mustelin, T. (2005).
Cooperative phosphorylation of the
tumor suppressor phosphatase and
tensin homologue (PTEN) by casein
kinases and glycogen synthase kinase
3beta. J. Biol. Chem. 280, 35195–
35202.
Aman, M. J., Walk, S. F., March, M. E.,
Su, H. P., Carver, D. J., and Ravichan-
dran, K. S. (2000). Essential role for
the C-terminal noncatalytic region
of SHIP in FcgammaRIIB1-mediated
inhibitory signaling. Mol. Cell. Biol.
20, 3576–3589.
Amin, R. H., and Schlissel, M.
S. (2008). Foxo1 directly regulates
the transcription of recombination-
activating genes during B cell
development. Nat. Immunol. 9,
613–622.
Anderson, K. E., Coadwell, J., Stephens,
L. R., and Hawkins, P. T. (1998).
Translocationof PDK-1 to the plasma
membrane is important in allowing
PDK-1 to activate protein kinase B.
Curr. Biol. 8, 684–691.
Anzelon, A. N., Wu, H., and Rickert,
R. C. (2003). Pten inactivation alters
peripheral B lymphocyte fate and
reconstitutes CD19 function. Nat.
Immunol. 4, 287–294.
Arana, E., Vehlow, A., Harwood, N.
E., Vigorito, E., Henderson, R.,
Turner, M., Tybulewicz, V. L., and
Batista, F. D. (2008). Activation of
the small GTPase Rac2 via the B cell
receptor regulates B cell adhesion
and immunological-synapse forma-
tion. Immunity 28, 88–99.
Arron, J. R., Vologodskaia, M., Wong,
B. R., Naramura, M., Kim, N., Gu,
H., and Choi, Y. (2001). A positive
regulatory role for Cbl family pro-
teins in tumor necrosis factor-related
activation-induced cytokine (trance)
and CD40L-mediated Akt activation.
J. Biol. Chem. 276, 30011–30017.
Astoul, E., Watton, S., and Cantrell,
D. (1999). The dynamics of protein
kinase B regulation during B cell anti-
gen receptor engagement. J. Cell Biol.
145, 1511–1520.
Balatti, V., Bottoni, A., Palamarchuk, A.,
Alder, H., Rassenti, L. Z., Kipps, T. J.,
Pekarsky,Y., and Croce, C. M. (2012).
NOTCH1 mutations in CLL asso-
ciated with trisomy 12. Blood 119,
329–331.
Barragan, M., Bellosillo, B., Campas,
C., Colomer, D., Pons, G., and Gil,
J. (2002). Involvement of protein
kinase C and phosphatidylinositol 3-
kinase pathways in the survival of
B-cell chronic lymphocytic leukemia
cells. Blood 99, 2969–2976.
Barragan, M., de Frias, M., Iglesias-
Serret, D., Campas, C., Castano,
E., Santidrian, A. F., Coll-Mulet, L.,
Cosialls, A. M., Domingo, A., Pons,
G., and Gil, J. (2006). Regulation of
Akt/PKB by phosphatidylinositol 3-
kinase-dependent and -independent
pathways in B-cell chronic lympho-
cytic leukemia cells: role of protein
kinase C{beta}. J. Leukoc. Biol. 80,
1473–1479.
Beer-Hammer, S., Zebedin, E., von
Holleben, M., Alferink, J., Reis, B.,
Dresing, P., Degrandi, D., Scheu,
S., Hirsch, E., Sexl, V., Pfeffer,
K., Nurnberg, B., and Piekorz, R.
P. (2010). The catalytic PI3K iso-
forms p110gamma and p110delta
contribute to B cell development and
maintenance, transformation, and
proliferation. J. Leukoc. Biol. 87,
1083–1095.
Beitz, L. O., Fruman, D. A., Kurosaki,
T., Cantley, L. C., and Scharenberg,
A. M. (1999). SYK is upstream of
phosphoinositide 3-kinase in B cell
receptor signaling. J. Biol. Chem. 274,
32662–32666.
Bilancio, A., Okkenhaug, K., Camps,
M., Emery, J. L., Ruckle, T., Rommel,
C., and Vanhaesebroeck, B. (2006).
Key role of the p110delta isoform of
PI3K inB-cell antigen and IL-4 recep-
tor signaling: comparative analysis
of genetic and pharmacologic inter-
ference with p110delta function in
B cells. Blood 107, 642–650.
Blaeser, F., Bryce, P. J., Ho, N., Raman,
V., Dedeoglu, F., Donaldson, D. D.,
Geha, R. S., Oettgen, H. C., and
Chatila, T. A. (2003). Targeted inac-
tivation of the IL-4 receptor alpha
chain I4Rmotif promotes allergic air-
way inﬂammation. J. Exp. Med. 198,
1189–1200.
Bolland, S., Pearse, R. N., Kurosaki, T.,
and Ravetch, J. V. (1998). SHIP mod-
ulates immune receptor responses by
regulating membrane association of
Btk. Immunity 8, 509–516.
Boulanger, E., Marchio, A., Hong, S.
S., and Pineau, P. (2009). Mutational
analysis of TP53, PTEN, PIK3CA
and CTNNB1/beta-catenin genes in
human herpesvirus 8-associated pri-
mary effusion lymphoma. Haemato-
logica 94, 1170–1174.
Brauweiler, A., Tamir, I., Dal Porto,
J., Benschop, R. J., Helgason, C. D.,
Humphries, R. K., Freed, J. H., and
Cambier, J. C. (2000). Differential
regulation of B cell development,
activation, and death by the src
homology 2 domain-containing 5′
inositol phosphatase (SHIP). J. Exp.
Med. 191, 1545–1554.
Brooks, R., Fuhler, G. M., Iyer, S., Smith,
M. J., Park, M. Y., Paraiso, K. H.,
Engelman, R. W., and Kerr, W. G.
(2010). SHIP1 inhibition increases
immunoregulatory capacity and trig-
gers apoptosis of hematopoietic
cancer cells. J. Immunol. 184,
3582–3589.
Brown, J. R., Jahn, T. M., Furman, R. R.,
Leonard, J. P., Spurgeon, S. E., Byrd,
J. C., Benson, D. M., Coutre, S. E.,
Wagner-Johnston, N. D., Flinn, I. W.,
Kahl, B. S., Schreeder, M. T., Vos de,
S., Holes, L. M., Peterman, H., John-
son, D. M., and Miller, L. L. (2011).
“Patterns of nodal response and lym-
phocytosis in patients with previ-
ously treated chronic lymphocytic
leukemia (CLL) receiving the selec-
tive phosphatidylinositol 3-kinase-
delta (PI3Kd) inhibitor, CAL-101
(GS-1101) alone or in combina-
tion with rituximab or bendamus-
tine,” in 14th International Workshop
on Chronic Lymphocytic Leukemia,
28–30 October 2011, Houston,
TX, USA.
Brown, J. R., Levine, R. L., Thomp-
son, C., Basile, G., Gilliland, D. G.,
and Freedman, A. S. (2008). Sys-
tematic genomic screen for tyrosine
kinase mutations in CLL. Leukemia
22, 1966–1969.
Browne, C. D., Del Nagro, C. J., Cato,
M. H., Dengler, H. S., and Rickert,
R. C. (2009). Suppression of phos-
phatidylinositol 3,4,5-trisphosphate
production is a key determinant of
B cell anergy. Immunity 31, 749–760.
Buchner, M., Fuchs, S., Prinz, G.,
Pfeifer, D., Bartholome, K., Burger,
M., Chevalier, N., Vallat, L., Tim-
mer, J., Gribben, J. G., Jumaa, H.,
Veelken, H., Dierks, C., and Zirlik, K.
(2009). Spleen tyrosine kinase is over-
expressed and represents a potential
therapeutic target in chronic lym-
phocytic leukemia. Cancer Res. 69,
5424–5432.
www.frontiersin.org August 2012 | Volume 3 | Article 224 | 13
“ﬁmmu-03-00224” — 2012/8/7 — 17:39 — page 14 — #14
Pauls et al. PI3K pathway in B cells
Buhl, A. M., Pleiman, C. M., Rickert, R.
C., and Cambier, J. C. (1997). Qual-
itative regulation of B cell antigen
receptor signaling by CD19: selec-
tive requirement for PI3-kinase acti-
vation, inositol-1,4,5-trisphosphate
production and Ca2+ mobilization.
J. Exp. Med. 186, 1897–1910.
Burger, J. A., Burger, M., and Kipps,
T. J. (1999). Chronic lymphocytic
leukemia B cells express func-
tional CXCR4 chemokine receptors
that mediate spontaneous migration
beneath bone marrow stromal cells.
Blood 94, 3658–3667.
Burgering, B. M., and Coffer, P. J.
(1995). Protein kinase B (c-Akt)
in phosphatidylinositol-3-OH kinase
signal transduction. Nature 376,
599–602.
Burke, J. E., Vadas, O., Berndt, A., Fine-
gan, T., Perisic, O., and Williams, R.
L. (2011). Dynamics of the phospho-
inositide 3-kinase p110delta interac-
tion with p85alpha and membranes
reveals aspects of regulation dis-
tinct from p110alpha. Structure 19,
1127–1137.
Burkle, A., Niedermeier, M., Schmitt-
Graff, A., Wierda, W. G., Keating, M.
J., and Burger, J. A. (2007). Over-
expression of the CXCR5 chemokine
receptor, and its ligand, CXCL13 in
B-cell chronic lymphocytic leukemia.
Blood 110, 3316–3325.
Cajiao, I., Sargent, R., Elstrom, R.,
Cooke, N. E., Bagg, A., and Lieb-
haber, S. A. (2007). Igbeta(CD79b)
mRNA expression in chronic lym-
phocytic leukaemia cells correlates
with immunoglobulin heavy chain
gene mutational status but does not
serve as an independent predictor of
clinical severity. Am. J. Hematol. 82,
712–720.
Calamito, M., Juntilla, M. M., Thomas,
M., Northrup, D. L., Rathmell, J.,
Birnbaum, M. J., Koretzky, G., and
Allman, D. (2010). Akt1 and Akt2
promote peripheral B-cell matura-
tion and survival. Blood 115, 4043–
4050.
Calpe, E., Codony, C., Baptista, M. J.,
Abrisqueta, P., Carpio, C., Purroy,
N., Bosch, F., and Crespo, M. (2011).
ZAP-70 enhancesmigrationof malig-
nant B lymphocytes toward CCL21
by inducing CCR7 expression via
IgM-ERK1/2 activation. Blood 118,
4401–4410.
Cannons, J. L., Qi, H., Lu, K. T.,
Dutta, M., Gomez-Rodriguez, J.,
Cheng, J., Wakeland, E. K., Ger-
main, R. N., and Schwartzberg,
P. L. (2010). Optimal germinal
center responses require a multi-
stage T cell:B cell adhesion process
involving integrins, SLAM-associated
protein, and CD84. Immunity 32,
253–265.
Capitani, N., Lucherini, O. M., Sozzi,
E., Ferro, M., Giommoni, N., Finetti,
F., De Falco, G., Cencini, E., Ras-
padori, D., Pelicci, P. G., Lauria, F.,
Forconi, F., and Baldari, C. T. (2010).
Impaired expression of p66Shc, a
novel regulator of B-cell survival, in
chronic lymphocytic leukemia. Blood
115, 3726–3736.
Carpenter, C. L., Auger, K. R., Chanud-
huri, M., Yoakim, M., Schaffhausen,
B., Shoelson, S., and Cantley, L.
C. (1993). Phosphoinositide 3-kinase
is activated by phosphopeptides that
bind to the SH2 domains of the 85-
kDa subunit. J. Biol. Chem. 268,
9478–9483.
Carter, R. H., and Fearon, D. T. (1992).
CD19: lowering the threshold for
antigen receptor stimulation of B
lymphocytes. Science 256, 105–107.
Castillo, J. J., Furman, M., and
Winer, E. S. (2012). CAL-101: a
phosphatidylinositol-3-kinase p110-
delta inhibitor for the treatment of
lymphoid malignancies. Expert Opin.
Investig. Drugs 21, 15–22.
Chagpar, R. B., Links, P. H., Pastor, M.
C., Furber, L. A., Hawrysh, A. D.,
Chamberlain, M. D., and Anderson,
D. H. (2010). Direct positive regula-
tion of PTEN by the p85 subunit of
phosphatidylinositol 3-kinase. Proc.
Natl. Acad. Sci. U.S.A. 107, 5471–
5476.
Chantry, D., Vojtek, A., Kashishian,
A., Holtzman, D. A., Wood, C.,
Gray, P. W., Cooper, J. A., and
Hoekstra, M. F. (1997). p110delta,
a novel phosphatidylinositol 3-kinase
catalytic subunit that associates with
P85 and is expressed predominantly
in leukocytes. J. Biol. Chem. 272,
19236–19241.
Chen, J., Limon, J. J., Blanc, C., Peng,
S. L., and Fruman, D. A. (2010).
Foxo1 regulates marginal zone B-cell
development. Eur. J. Immunol. 40,
1890–1896.
Chen, L., Apgar, J., Huynh, L., Dicker,
F., Giago-McGahan, T., Rassenti, L.,
Weiss, A., and Kipps, T. J. (2005).
ZAP-70 directly enhances IgM signal-
ing in chronic lymphocytic leukemia.
Blood 105, 2036–2041.
Chen, L., Huynh, L., Apgar, J., Tang, L.,
Rassenti, L.,Weiss, A., and Kipps, T. J.
(2008). ZAP-70 enhances IgM signal-
ing independent of its kinase activ-
ity in chronic lymphocytic leukemia.
Blood 111, 2685–2692.
Chen, L., Juszczynski, P., Takeyama,
K., Aguiar, R. C., and Shipp, M. A.
(2006). Protein tyrosine phosphatase
receptor-type O truncated (PTPROt)
regulates SYK phosphorylation,
proximal B-cell-receptor signaling,
and cellular proliferation. Blood 108,
3428–3433.
Chen, S. S., Buggy, J., Burger, J. A., and
Chiorazzi, N. (2011). “Btk inhibitor,
PCI-32765, delaysCLLprogression in
a TCL1 adoptive transfer model by
impairingmigration and cell prolifer-
ation,” in 14th InternationalWorkshop
on Chronic Lymphocytic Leukemia,
28–30 October 2011, Houston, TX,
USA.
Cheson, B. D., Bennett, J. M., Grever,
M., Kay, N., Keating, M. J., O’Brien,
S., and Rai, K. R. (1996). National
Cancer Institute-sponsored Working
Group guidelines for chronic lym-
phocytic leukemia: revised guidelines
for diagnosis and treatment. Blood
87, 4990–4997.
Cheung, S. M., Kornelson, J. C.,
Al-Alwan, M., and Marshall, A.
J. (2007). Regulation of phospho-
inositide 3-kinase signaling by oxi-
dants: hydrogen peroxide selectively
enhances immunoreceptor-induced
recruitment of phosphatidylinosi-
tol (3,4) bisphosphate-binding PH
domain proteins. Cell. Signal. 19,
902–912.
Chiu, C. W., Dalton, M., Ishiai, M.,
Kurosaki, T., and Chan, A. C.
(2002). BLNK: molecular scaffolding
through ‘cis’-mediated organization
of signaling proteins. EMBO J. 21,
6461–6472.
Clayton, E., Bardi, G., Bell, S. E.,
Chantry, D., Downes, C. P., Gray,
A., Humphries, L. A., Rawlings,
D., Reynolds, H., Vigorito, E., and
Turner, M. (2002). A crucial role
for the p110delta subunit of phos-
phatidylinositol 3-kinase in B cell
development and activation. J. Exp.
Med. 196, 753–763.
Condliffe, A. M., Davidson, K., Ander-
son, K. E., Ellson, C. D., Crabbe, T.,
Okkenhaug, K., Vanhaesebroeck, B.,
Turner, M., Webb, L., Wymann, M.
P., Hirsch, E., Ruckle, T., Camps, M.,
Rommel, C., Jackson, S. P., Chilvers,
E. R., Stephens, L. R., and Hawkins,
P. T. (2005). Sequential activation
of class IB and class IA PI3K is
important for the primed respira-
tory burst of human but not murine
neutrophils. Blood 106, 1432–1440.
Contri, A., Brunati, A. M., Trentin,
L., Cabrelle, A., Miorin, M., Cesaro,
L., Pinna, L. A., Zambello, R.,
Semenzato, G., and Donella-Deana,
A. (2005). Chronic lymphocytic
leukemia B cells contain anomalous
Lyn tyrosine kinase, a putative contri-
bution to defective apoptosis. J. Clin.
Invest. 115, 369–378.
Costinean, S., Sandhu, S. K., Pedersen,
I. M., Tili, E., Trotta, R., Perrotti,
D., Ciarlariello, D., Neviani, P., Harb,
J., Kauffman, L. R., Shidham, A.,
and Croce, C. M. (2009). Src homol-
ogy 2 domain-containing inositol-5-
phosphatase and CCAAT enhancer-
binding protein beta are targeted
by miR-155 in B cells of Emicro-
MiR-155 transgenic mice. Blood 114,
1374–1382.
Costinean, S., Zanesi, N., Pekarsky,
Y., Tili, E., Volinia, S., Heerema,
N., and Croce, C. M. (2006). Pre-
B cell proliferation and lymphoblas-
tic leukemia/high-grade lymphoma
in E(mu)-miR155 transgenic mice.
Proc. Natl. Acad. Sci. U.S.A. 103,
7024–7029.
Crespo, M., Bosch, F., Villamor, N.,
Bellosillo, B., Colomer, D., Rozman,
M., Marce, S., Lopez-Guillermo,
A., Campo, E., and Montserrat, E.
(2003). ZAP-70 expression as a sur-
rogate for immunoglobulin-variable-
region mutations in chronic lympho-
cytic leukemia. N. Engl. J. Med. 348,
1764–1775.
Deane, J. A., and Fruman, D. A.
(2004). Phosphoinositide 3-kinase:
diverse roles in immune cell acti-
vation. Annu. Rev. Immunol. 22,
563–598.
DeFranco, A. L. (2001). Vav and the
B cell signalosome. Nat. Immunol. 2,
482–484.
Del Giudice, I., Rossi, D., Chiaretti,
S., Marinelli, M., Tavolaro, S.,
Gabrielli, S., Laurenti, L., Marasca,
R., Rasi, S., Fangazio, M., Guarini,
A., Gaidano, G., and Foa, R. (2012).
NOTCH1 mutations in +12 chronic
lymphocytic leukemia (CLL) confer
an unfavorable prognosis, induce a
distinctive transcriptional proﬁling
and reﬁne the intermediate progno-
sis of +12 CLL. Haematologica 97,
437–441.
Delgado, P., Cubelos, B., Calleja,
E., Martinez-Martin, N., Cipres,
A., Merida, I., Bellas, C., Bustelo,
X. R., and Alarcon, B. (2009).
Essential function for the GTPase
TC21 in homeostatic antigen recep-
tor signaling. Nat. Immunol. 10,
880–888.
Dengler, H. S., Baracho, G. V., Omori,
S. A., Bruckner, S., Arden, K. C.,
Castrillon, D. H., DePinho, R. A.,
and Rickert, R. C. (2008). Distinct
functions for the transcription fac-
tor Foxo1 at various stages of B cell
differentiation. Nat. Immunol. 9,
1388–1398.
Depoil, D., Fleire, S., Treanor, B. L.,
Weber, M., Harwood, N. E., March-
bank, K. L., Tybulewicz, V. L., and
Batista, F. D. (2008). CD19 is essen-
tial for B cell activation by promoting
B cell receptor-antigen microcluster
Frontiers in Immunology | B Cell Biology August 2012 | Volume 3 | Article 224 | 14
“ﬁmmu-03-00224” — 2012/8/7 — 17:39 — page 15 — #15
Pauls et al. PI3K pathway in B cells
formation in response to membrane-
bound ligand. Nat. Immunol. 9,
63–72.
de Rooij, M. F., Kuil, A., Geest, C. R.,
Eldering, E., Chang, B. Y., Buggy,
J. J., Pals, S. T., and Spaargaren,
M. (2012). The clinically active BTK
inhibitor PCI-32765 targets B-cell
receptor- and chemokine-controlled
adhesion and migration in chronic
lymphocytic leukemia. Blood 119,
2590–2594.
Dil, N., and Marshall, A. J. (2009). Role
of phosphoinositide 3-kinase p110
delta in TLR4- and TLR9-mediated
B cell cytokine production and differ-
entiation. Mol. Immunol. 46, 1970–
1978.
Donahue, A. C., Hess, K. L., Ng, K. L.,
and Fruman, D. A. (2004). Altered
splenic B cell subset development
in mice lacking phosphoinositide 3-
kinase p85alpha. Int. Immunol. 16,
1789–1798.
Dowler, S., Currie, R. A., Camp-
bell, D. G., Deak, M., Kular, G.,
Downes, C. P., and Alessi, D. R.
(2000). Identiﬁcation of pleckstrin-
homology-domain-containing pro-
teins with novel phosphoinositide-
binding speciﬁcities. Biochem. J. 351,
19–31.
Durand, C. A., Hartvigsen, K., Fogel-
strand, L., Kim, S., Iritani, S., Van-
haesebroeck, B., Witztum, J. L., Puri,
K. D., and Gold, M. R. (2009). Phos-
phoinositide 3-kinase p110 delta reg-
ulates natural antibody production,
marginal zone and B-1 B cell func-
tion, and autoantibody responses. J.
Immunol. 183, 5673–5684.
Efremov, D. G., and Laurenti, L. (2011).
The Syk kinase as a therapeutic
target in leukemia and lymphoma.
Expert Opin. Investig. Drugs 20,
623–636.
Eis, P. S., Tam, W., Sun, L., Chadburn,
A., Li, Z., Gomez, M. F., Lund, E., and
Dahlberg, J. E. (2005). Accumulation
of miR-155 and BIC RNA in human
B cell lymphomas. Proc. Natl. Acad.
Sci. U.S.A. 102, 3627–3632.
Engels, N., Wollscheid, B., and Wien-
ands, J. (2001). Association of SLP-
65/BLNK with the B cell antigen
receptor through a non-ITAM tyro-
sine of Ig-alpha. Eur. J. Immunol. 31,
2126–2134.
Fabbri, G., Rasi, S., Rossi, D., Tri-
fonov, V., Khiabanian, H., Ma, J.,
Grunn, A., Fangazio, M., Capello,
D., Monti, S., Cresta, S., Gargiulo,
E., Forconi, F., Guarini, A., Arcaini,
L., Paulli, M., Laurenti, L., Larocca,
L. M., Marasca, R., Gattei, V.,
Oscier, D., Bertoni, F., Mullighan,
C. G., Foa, R., Pasqualucci, L.,
Rabadan, R., Dalla-Favera, R., and
Gaidano, G. (2011). Analysis of the
chronic lymphocytic leukemia cod-
ing genome: role of NOTCH1 muta-
tional activation. J. Exp. Med. 208,
1389–1401.
Frech, M., Andjelkovic, M., Ingley, E.,
Reddy, K. K., Falck, J. R., and Hem-
mings, B. A. (1997). High afﬁnity
binding of inositol phosphates and
phosphoinositides to the pleckstrin
homology domain of RAC/protein
kinase B and their inﬂuence on kinase
activity. J. Biol. Chem. 272, 8474–
8481.
Fruman, D. A., and Bismuth, G. (2009).
Fine tuning the immune response
with PI3K. Immunol. Rev. 228, 253–
272.
Fruman, D. A., Snapper, S. B., Yballe,
C. M., Davidson, L., Yu, J. Y., Alt,
F. W., and Cantley, L. C. (1999).
Impaired B cell development and
proliferation in absence of phospho-
inositide 3-kinase p85alpha. Science
283, 393–397.
Fuhler, G. M., Brooks, R., Toms, B., Iyer,
S., Gengo, E. A., Park, M. Y., Gum-
bleton, M., Viernes, D. R., Chisholm,
J. D., and Kerr, W. G. (2012). Ther-
apeutic potential of SH2 domain-
containing inositol-5′-phosphatase 1
(SHIP1) and SHIP2 inhibition in
cancer. Mol. Med. 18, 65–75.
Fujimoto, M., Fujimoto, Y., Poe, J.
C., Jansen, P. J., Lowell, C. A.,
DeFranco, A. L., and Tedder, T.
F. (2000). CD19 regulates Src fam-
ily protein tyrosine kinase activa-
tion in B lymphocytes through pro-
cessive ampliﬁcation. Immunity 13,
47–57.
Fukuda, R., Hayashi, A., Utsunomiya,
A., Nukada, Y., Fukui, R., Itoh, K.,
Tezuka, K., Ohashi, K., Mizuno,
K., Sakamoto, M., Hamanoue,
M., and Tsuji, T. (2005). Alter-
ation of phosphatidylinositol 3-
kinase cascade in the multilobulated
nuclear formation of adult T cell
leukemia/lymphoma (ATLL). Proc.
Natl. Acad. Sci. U.S.A. 102, 15213–
15218.
Gabelloni, M. L., Borge, M., Galletti, J.,
Canones, C., Calotti, P. F., Bezares,
R. F., Avalos, J. S., Giordano, M.,
and Gamberale, R. (2008). SHIP-
1 protein level and phosphorylation
status differs between CLL cells seg-
regated by ZAP-70 expression. Br. J.
Haematol. 140, 117–119.
Georgakis, G. V., Li, Y., Rassidakis,
G. Z., Medeiros, L. J., Mills, G.
B., and Younes, A. (2006). Inhi-
bition of the phosphatidylinositol-3
kinase/Akt promotes G1 cell cycle
arrest and apoptosis in Hodgkin lym-
phoma. Br. J. Haematol. 132, 503–
511.
Gewinner, C., Wang, Z. C., Richard-
son, A., Teruya-Feldstein, J., Etemad-
moghadam, D., Bowtell, D., Bar-
retina, J., Lin, W. M., Rameh,
L., Salmena, L., Pandolﬁ, P. P.,
and Cantley, L. C. (2009). Evi-
dence that inositol polyphosphate 4-
phosphatase type II is a tumor sup-
pressor that inhibits PI3K signaling.
Cancer Cell 16, 115–125.
Gobessi, S., Laurenti, L., Longo, P. G.,
Sica, S., Leone, G., and Efremov,
D. G. (2007). ZAP-70 enhances B-
cell-receptor signaling despite absent
or inefﬁcient tyrosine kinase activa-
tion in chronic lymphocytic leukemia
and lymphoma B cells. Blood 109,
2032–2039.
Gold, M. R., and Aebersold, R.
(1994). Both phosphatidylinositol 3-
kinase and phosphatidylinositol 4-
kinase products are increased by anti-
gen receptor signaling in B cells. J.
Immunol. 152, 42–50.
Granboulan, M., Lankar, D., Raposo,
G., Bonnerot, C., and Hivroz, C.
(2003). Phosphoinositide 3-kinase
activation by Igbeta controls de novo
formation of an antigen-processing
compartment. J. Biol. Chem. 278,
4331–4338.
Gronbaek, K., Zeuthen, J., Guld-
berg, P., Ralfkiaer, E., and Hou-
Jensen, K. (1998). Alterations of the
MMAC1/PTEN gene in lymphoid
malignancies. Blood 91, 4388–4390.
Gu, H., Maeda, H., Moon, J. J., Lord,
J. D., Yoakim, M., Nelson, B. H., and
Neel, B. G. (2000). New role for Shc
in activationof the phosphatidylinos-
itol 3-kinase/Akt pathway. Mol. Cell.
Biol. 20, 7109–7120.
Gutierrez, N. C., Ocio, E. M., de Las
Rivas, J., Maiso, P., Delgado, M., Fer-
minan, E., Arcos, M. J., Sanchez, M.
L., Hernandez, J. M., and San Miguel,
J. F. (2007). Gene expression pro-
ﬁling of B lymphocytes and plasma
cells fromWaldenström’s macroglob-
ulinemia: comparison with expres-
sion patterns of the same cell coun-
terparts from chronic lymphocytic
leukemia, multiple myeloma and
normal individuals. Leukemia 21,
541–549.
Hallek, M., Cheson, B. D., Catovsky,
D., Caligaris-Cappio, F., Dighiero,
G., Dohner, H., Hillmen, P., Keat-
ing, M. J., Montserrat, E., Rai,
K. R., and Kipps, T. J. (2008).
Guidelines for the diagnosis and
treatment of chronic lymphocytic
leukemia: a report from the Interna-
tional Workshop on Chronic Lym-
phocytic Leukemia updating the
National Cancer Institute-Working
Group 1996 guidelines. Blood 111,
5446–5456.
Hancock, J. T., Henderson, L. M., and
Jones, O. T. (1990). Superoxide gen-
eration by EBV-transformed B lym-
phocytes. Activation by IL-1 beta,
TNF-alpha and receptor independent
stimuli. Immunology 71, 213–217.
Harris, M. B., Chang, C. C., Berton,
M. T., Danial, N. N., Zhang, J.,
Kuehner, D., Ye, B. H., Kvatyuk,
M., Pandolﬁ, P. P., Cattoretti, G.,
Dalla-Favera, R., and Rothman, P.
B. (1999). Transcriptional repres-
sion of Stat6-dependent interleukin-
4-induced genes by BCL-6: speciﬁc
regulation of iepsilon transcription
and immunoglobulin E switching.
Mol. Cell. Biol. 19, 7264–7275.
Harris, S. J., Parry, R. V., Foster, J.
G., Blunt, M. D., Wang, A., Marelli-
Berg, F., Westwick, J., and Ward, S.
G. (2011). Evidence that the lipid
phosphatase SHIP-1 regulates T lym-
phocyte morphology and motility. J.
Immunol. 186, 4936–4945.
Helgason, C. D., Damen, J. E., Rosten,
P., Grewal, R., Sorensen, P., Chap-
pel, S. M., Borowski, A., Jirik, F.,
Krystal, G., and Humphries, R. K.
(1998). Targeted disruption of SHIP
leads to hemopoietic perturbations,
lung pathology, and a shortened life
span. Genes Dev. 12, 1610–1620.
Helgason, C. D., Kalberer, C. P., Damen,
J. E., Chappel, S. M., Pineault, N.,
Krystal, G., and Humphries, R. K.
(2000). A dual role for Src homol-
ogy 2 domain-containing inositol-
5-phosphatase (SHIP) in immu-
nity: aberrant development and
enhanced function of b lymphocytes
in ship−/− mice. J. Exp. Med. 191,
781–794.
Henley, T., Kovesdi, D., and Turner,
M. (2008). B-cell responses to B-cell
activation factor of the TNF family
(BAFF) are impaired in the absence
of PI3K delta. Eur. J. Immunol. 38,
3543–3548.
Herman, S. E., Gordon, A. L., Hertlein,
E., Ramanunni, A., Zhang, X.,
Jaglowski, S., Flynn, J., Jones, J.,
Blum, K. A., Buggy, J. J., Hamdy,
A., Johnson, A. J., and Byrd, J. C.
(2011). Bruton tyrosine kinase repre-
sents a promising therapeutic target
for treatment of chronic lymphocytic
leukemia and is effectively targeted by
PCI-32765. Blood 117, 6287–6296.
Herman, S. E.,Gordon,A. L.,Wagner,A.
J., Heerema, N. A., Zhao,W., Flynn, J.
M., Jones, J.,Andritsos, L., Puri, K.D.,
Lannutti, B. J., Giese, N. A., Zhang,
X., Wei, L., Byrd, J. C., and John-
son, A. J. (2010). Phosphatidylinosi-
tol 3-kinase-delta inhibitor CAL-101
shows promising preclinical activity
in chronic lymphocytic leukemia by
antagonizing intrinsic and extrinsic
www.frontiersin.org August 2012 | Volume 3 | Article 224 | 15
“ﬁmmu-03-00224” — 2012/8/7 — 17:39 — page 16 — #16
Pauls et al. PI3K pathway in B cells
cellular survival signals. Blood 116,
2078–2088.
Hoellenriegel, J., Meadows, S. A., Sivina,
M., Wierda, W. G., Kantarjian, H.,
Keating, M. J., Giese, N., O’Brien, S.,
Yu,A.,Miller, L. L., Lannutti, B. J., and
Burger, J. A. (2011). The phospho-
inositide 3′-kinase delta inhibitor,
CAL-101, inhibits B-cell receptor sig-
naling and chemokine networks in
chronic lymphocytic leukemia. Blood
118, 3603–3612.
Hon,W. C., Berndt, A., andWilliams, R.
L. (2011). Regulation of lipid binding
underlies the activation mechanism
of class IA PI3-kinases. Oncogene.
doi: 10.1038/onc.2011.532 [Epub
ahead of print].
Hu, L., Zaloudek, C., Mills, G. B., Gray,
J., and Jaffe, R. B. (2000). In vivo and
in vitro ovarian carcinoma growth
inhibition by a phosphatidylinositol
3-kinase inhibitor (LY294002). Clin.
Cancer Res. 6, 880–886.
Ihle, N. T., Williams, R., Chow, S.,
Chew, W., Berggren, M. I., Paine-
Murrieta, G., Minion, D. J., Halter, R.
J., Wipf, P., Abraham, R., Kirkpatrick,
L., and Powis, G. (2004). Molecular
pharmacology and antitumor activ-
ity of PX-866, a novel inhibitor of
phosphoinositide-3-kinase signaling.
Mol. Cancer Ther. 3, 763–772.
Ikeda, H., Hideshima, T., Fulciniti, M.,
Perrone, G., Miura, N., Yasui, H.,
Okawa, Y., Kiziltepe, T., Santo, L.,
Vallet, S., Cristea, D., Calabrese, E.,
Gorgun, G., Raje, N. S., Richardson,
P.,Munshi, N. C., Lannutti, B. J., Puri,
K. D., Giese, N. A., and Anderson,
K. C. (2010). PI3K/p110{delta} is a
novel therapeutic target in multiple
myeloma. Blood 116, 1460–1468.
Ismail, S. I., Mahmoud, I. S., Msallam,
M. M., and Sughayer, M. A. (2010).
Hotspot mutations of PIK3CA and
AKT1 genes are absent in multiple
myeloma. Leuk. Res. 34, 824–826.
Isnardi, I., Bruhns, P., Bismuth,G., Frid-
man, W. H., and Daeron, M. (2006).
The SH2 domain-containing inosi-
tol 5-phosphatase SHIP1 is recruited
to the intracytoplasmic domain of
human FcgammaRIIB and is manda-
tory for negative regulation of B cell
activation. Immunol. Lett. 104, 156–
165.
Isnardi, I., Lesourne, R., Bruhns, P.,
Fridman, W. H., Cambier, J. C.,
and Daeron, M. (2004). Two dis-
tinct tyrosine-basedmotifs enable the
inhibitory receptor FcgammaRIIB
to cooperatively recruit the inosi-
tol phosphatases SHIP1/2 and the
adapters Grb2/Grap. J. Biol. Chem.
279, 51931–51938.
Ivetac, I., Gurung, R., Hakim, S., Horan,
K. A., Shefﬁeld, D. A., Binge, L.
C., Majerus, P. W., Tiganis, T., and
Mitchell, C. A. (2009). Regulation
of PI(3)K/Akt signalling and cellular
transformation by inositol polyphos-
phate 4-phosphatase-1. EMBO Rep.
10, 487–493.
Janas, M. L., Hodson, D., Stamataki, Z.,
Hill, S., Welch, K., Gambardella, L.,
Trotman, L. C., Pandolﬁ, P. P., Vig-
orito, E., and Turner, M. (2008). The
effect of deleting p110delta on the
phenotype and function of PTEN-
deﬁcient B cells. J. Immunol. 180,
739–746.
Jimenez, C., Hernandez, C., Pimentel,
B., andCarrera,A. C. (2002). The p85
regulatory subunit controls sequen-
tial activation of phosphoinositide
3-kinase by Tyr kinases and Ras. J.
Biol. Chem. 277, 41556–41562.
Jones, D. T., Ganeshaguru, K., Ander-
son, R. J., Jackson, T. R., Bruckdorfer,
K. R., Low, S. Y., Palmqvist, L., Pren-
tice, H. G., Hoffbrand, A. V., Mehta,
A. B., and Wickremasinghe, R. G.
(2003). Albumin activates the AKT
signaling pathway and protects B-
chronic lymphocytic leukemia cells
from chlorambucil- and radiation-
induced apoptosis. Blood 101, 3174–
3180.
Jou, S. T., Carpino, N., Takahashi, Y.,
Piekorz, R., Chao, J. R.,Wang, D., and
Ihle, J. N. (2002). Essential, nonre-
dundant role for the phosphoinosi-
tide 3-kinase p110delta in signaling
by the B-cell receptor complex. Mol.
Cell. Biol. 22, 8580–8591.
Kanai, F., Liu, H., Field, S. J., Akbary,
H., Matsuo, T., Brown, G. E., Cant-
ley, L. C., andYaffe, M. B. (2001). The
PXdomains of p47phox andp40phox
bind to lipid products of PI(3)K. Nat.
Cell Biol. 3, 675–678.
Karlsson, M. C., Guinamard, R., Bol-
land, S., Sankala, M., Steinman,
R. M., and Ravetch, J. V. (2003).
Macrophages control the retention
and trafﬁcking of B lymphocytes in
the splenic marginal zone. J. Exp.
Med. 198, 333–340.
Kennah, M., Yau, T. Y., Nodwell, M.,
Krystal, G., Andersen, R. J., Ong, C.
J., and Mui, A. L. (2009). Activation
of SHIP via a small molecule ago-
nist kills multiple myeloma cells. Exp.
Hematol. 37, 1274–1283.
Kimura, T., Sakamoto, H., Appella,
E., and Siraganian, R. P. (1997).
The negative signaling molecule
SH2 domain-containing inositol-
polyphosphate 5-phosphatase
(SHIP) binds to the tyrosine-
phosphorylated beta subunit of
the high afﬁnity IgE receptor. J. Biol.
Chem. 272, 13991–13996.
King, C., Tangye, S. G., and Mackay,
C. R. (2008). T follicular helper
(TFH) cells in normal and dysregu-
lated immune responses. Annu. Rev.
Immunol. 26, 741–766.
Kluiver, J., Poppema, S., de Jong, D.,
Blokzijl, T., Harms, G., Jacobs, S.,
Kroesen, B. J., and van den Berg,
A. (2005). BIC and miR-155 are
highly expressed in Hodgkin, pri-
mary mediastinal and diffuse large
B cell lymphomas. J. Pathol. 207,
243–249.
Knight, Z. A., Gonzalez, B., Feldman,
M. E., Zunder, E. R., Goldenberg, D.
D., Williams, O., Loewith, R., Stokoe,
D., Balla, A., Toth, B., Balla, T., Weiss,
W. A., Williams, R. L., and Shokat, K.
M. (2006). A pharmacological map
of the PI3-K family deﬁnes a role for
p110alpha in insulin signaling. Cell
125, 733–747.
Kovesdi, D., Bell, S. E., and Turner, M.
(2010). The development of mature
B lymphocytes requires the combined
function of CD19 and the p110delta
subunit of PI3K. Self Nonself 1, 144–
153.
Krahn, A. K., Ma, K., Hou, S., Duro-
nio, V., and Marshall, A. J. (2004).
Two distinct waves of membrane-
proximal B cell antigen receptor
signaling differentially regulated by
Src homology 2-containing inosi-
tol polyphosphate 5-phosphatase. J.
Immunol. 172, 331–339.
Krause, M., Leslie, J. D., Stewart,
M., Lafuente, E. M., Valderrama,
F., Jagannathan, R., Strasser, G. A.,
Rubinson, D. A., Liu, H., Way, M.,
Yaffe, M. B., Boussiotis, V. A., and
Gertler, F. B. (2004). Lamellipodin, an
Ena/VASP ligand, is implicated in the
regulation of lamellipodial dynamics.
Dev. Cell 7, 571–583.
Kurosaki, T., Takata, M., Yamanashi, Y.,
Inazu, T., Taniguchi, T., Yamamoto,
T., and Yamamura, H. (1994). Syk
activation by the Src-family tyrosine
kinase in the B cell receptor signaling.
J. Exp. Med. 179, 1725–1729.
Kurtova, A. V., Balakrishnan, K., Chen,
R., Ding, W., Schnabl, S., Quiroga,
M. P., Sivina, M., Wierda, W. G.,
Estrov, Z., Keating, M. J., Shehata,
M., Jager, U., Gandhi, V., Kay, N.
E., Plunkett, W., and Burger, J.
A. (2009). Diverse marrow stromal
cells protect CLL cells from sponta-
neous and drug-induced apoptosis:
development of a reliable and repro-
ducible system to assess stromal cell
adhesion-mediated drug resistance.
Blood 114, 4441–4450.
Lam, K. P., Kuhn, R., and Rajew-
sky, K. (1997). In vivo ablation of
surface immunoglobulin on mature
B cells by inducible gene targeting
results in rapid cell death. Cell 90,
1073–1083.
Landego, I., Jayachandran, N.,
Wullschleger, S., Zhang, T. T.,
Gibson, I. W., Miller, A., Alessi,
D. R., and Marshall, A. J. (2012).
Interaction of TAPP adapter pro-
teins with phosphatidylinositol
(3,4)-bisphosphate regulates B-cell
activation and autoantibody produc-
tion. Eur. J. Immunol. doi: 10.1002/
eji.201242371 [Epub ahead of print].
Lannutti, B. J., Meadows, S. A., Her-
man, S. E., Kashishian, A., Steiner, B.,
Johnson, A. J., Byrd, J. C., Tyner, J.
W., Loriaux, M. M., Deininger, M.,
Druker, B. J., Puri, K. D., Ulrich, R.
G., and Giese, N. A. (2011). CAL-
101, a p110delta selective phosphati-
dylinositol-3-kinase inhibitor for the
treatment of B-cell malignancies,
inhibits PI3K signaling and cellular
viability. Blood 117, 591–594.
Lee, J. R., and Koretzky, G. A.
(1998). Production of reactive oxy-
gen intermediates following CD40
ligation correlates with c-Jun N-
terminal kinase activation and IL-6
secretion in murine B lymphocytes.
Eur. J. Immunol. 28, 4188–4197.
Lee, S. R., Yang, K. S., Kwon, J., Lee,
C., Jeong, W., and Rhee, S. G. (2002).
Reversible inactivation of the tumor
suppressor PTEN by H2O2. J. Biol.
Chem. 277, 20336–20342.
Lemmon, M. A., and Ferguson, K. M.
(2000). Signal-dependent membrane
targeting by pleckstrin homology
(PH) domains. Biochem. J. 350(Pt 1),
1–18.
Lenz, G., Wright, G. W., Emre, N. C.,
Kohlhammer, H., Dave, S. S., Davis,
R. E., Carty, S., Lam, L. T., Shaffer,
A. L., Xiao, W., Powell, J., Rosen-
wald, A., Ott, G., Muller-Hermelink,
H. K., Gascoyne, R. D., Connors, J.
M., Campo, E., Jaffe, E. S., Delabie, J.,
Smeland, E. B., Rimsza, L. M., Fisher,
R. I., Weisenburger, D. D., Chan, W.
C., and Staudt, L. M. (2008). Molec-
ular subtypes of diffuse large B-cell
lymphoma arise by distinct genetic
pathways. Proc. Natl. Acad. Sci. U.S.A.
105, 13520–13525.
Leslie, N. R., Bennett, D., Lindsay, Y. E.,
Stewart, H., Gray, A., and Downes,
C. P. (2003). Redox regulation of PI
3-kinase signalling via inactivation of
PTEN. EMBO J. 22, 5501–5510.
Leupin, N., Cenni, B., Novak, U., Hugli,
B., Graber, H. U., Tobler, A., and
Fey, M. F. (2003). Disparate expres-
sion of the PTEN gene: a novel
ﬁnding in B-cell chronic lymphocytic
leukaemia (B-CLL). Br. J. Haematol.
121, 97–100.
Lin, K. B., Freeman, S. A., Zabetian,
S., Brugger, H., Weber, M., Lei, V.,
Dang-Lawson, M., Tse, K. W., Santa-
maria, R., Batista, F. D., and Gold, M.
Frontiers in Immunology | B Cell Biology August 2012 | Volume 3 | Article 224 | 16
“ﬁmmu-03-00224” — 2012/8/7 — 17:39 — page 17 — #17
Pauls et al. PI3K pathway in B cells
R. (2008). The rap GTPases regulate
B cell morphology, immune-synapse
formation, and signaling by particu-
late B cell receptor ligands. Immunity
28, 75–87.
Liu, C., Miller, H., Hui, K. L., Grooman,
B., Bolland, S., Upadhyaya, A., and
Song, W. (2011). A balance of Bru-
ton’s tyrosine kinase and SHIP acti-
vation regulates B cell receptor clus-
ter formation by controlling actin
remodeling. J. Immunol. 187, 230–
239.
Liu, Q., Oliveira-Dos-Santos, A. J.,
Mariathasan, S., Bouchard, D., Jones,
J., Sarao, R., Kozieradzki, I., Ohashi,
P. S., Penninger, J. M., and Dumont,
D. J. (1998). The inositol polyphos-
phate 5-phosphatase ship is a crucial
negative regulator of B cell antigen
receptor signaling. J. Exp. Med. 188,
1333–1342.
Liu, Y. Y., Yao, S. N., Zhao, Y., Yao, Z.
H., Ma, J., Xia, Q. X., Fu, K., and
Yang, S. J. (2010). PTEN tumor sup-
pressor plays less prognostic role than
P53 tumor suppressor in diffuse large
B-cell lymphoma. Leuk. Lymphoma
51, 1692–1698.
Llorian, M., Stamataki, Z., Hill, S.,
Turner, M., and Martensson, I.
L. (2007). The PI3K p110delta is
required for down-regulation of RAG
expression in immature B cells. J.
Immunol. 178, 1981–1985.
Longo, P. G., Laurenti, L., Gobessi, S.,
Petlickovski, A., Pelosi, M., Chiu-
solo, P., Sica, S., Leone, G., and
Efremov, D. G. (2007). The Akt sig-
naling pathway determines the differ-
ent proliferative capacity of chronic
lymphocytic leukemia B-cells from
patients with progressive and stable
disease. Leukemia 21, 110–120.
Lu, T. T., and Cyster, J. G. (2002).
Integrin-mediated long-term B cell
retention in the splenic marginal
zone. Science 297, 409–412.
Lund, F. E. (2008). Cytokine-producing
B lymphocytes-key regulators of
immunity. Curr. Opin. Immunol. 20,
332–338.
Ma, K., Cheung, S. M., Marshall, A. J.,
and Duronio, V. (2008). PI(3,4,5)P3
and PI(3,4)P2 levels correlate with
PKB/akt phosphorylation at Thr308
and Ser473, respectively; PI(3,4)P2
levels determine PKB activity. Cell.
Signal. 20, 684–694.
Ma, S., and Rosen, S. T. (2011). Sig-
nal transduction inhibitors in chronic
lymphocytic leukemia. Curr. Opin.
Oncol. 23, 601–608.
Maccario, H., Perera, N. M., Davidson,
L., Downes, C. P., and Leslie, N. R.
(2007). PTEN is destabilized by phos-
phorylation on Thr366. Biochem. J.
405, 439–444.
Maehama, T., and Dixon, J. E.
(1998). The tumor suppressor,
PTEN/MMAC1, dephosphorylates
the lipid second messenger, phos-
phatidylinositol 3,4,5-trisphosphate.
J. Biol. Chem. 273, 13375–13378.
Maresco, D. L., Osborne, J. M., Cooney,
D., Coggeshall, K. M., and Anderson,
C. L. (1999). The SH2-containing 5′-
inositol phosphatase (SHIP) is tyro-
sine phosphorylated after Fc gamma
receptor clustering in monocytes. J.
Immunol. 162, 6458–6465.
Marone, R., Cmiljanovic, V., Giese, B.,
andWymann,M. P. (2008). Targeting
phosphoinositide 3-kinase: moving
towards therapy. Biochim. Biophys.
Acta 1784, 159–185.
Marshall, A. J., Krahn, A. K., Ma, K.,
Duronio, V., and Hou, S. (2002).
TAPP1 and TAPP2 are targets of
phosphatidylinositol 3-kinase signal-
ing in B cells: sustained plasma mem-
brane recruitment triggered by the
B-cell antigen receptor. Mol. Cell.
Biol. 22, 5479–5491.
Martin, P., Salas, C., Provencio, M.,
Abraira, V., and Bellas, C. (2011).
Heterogeneous expression of Src
tyrosine kinases Lyn, Fyn and Syk in
classical Hodgkin lymphoma: prog-
nostic implications. Leuk. Lymphoma
52, 2162–2168.
Martins, L. R., Lucio, P., Silva, M.
C., Gameiro, P., Silva, M. G., and
Barata, J. T. (2011). On CK2 regula-
tion of chronic lymphocytic leukemia
cell viability. Mol. Cell. Biochem. 356,
51–55.
Maxwell, M. J., Tsantikos, E., Kong, A.
M., Vanhaesebroeck, B., Tarlinton, D.
M., and Hibbs, M. L. (2012). Atten-
uation of phosphoinositide 3-kinase
delta signaling restrains autoimmune
disease. J. Autoimmun. 38, 381–391.
McConnachie, G., Pass, I.,Walker, S. M.,
and Downes, C. P. (2003). Interfacial
kinetic analysis of the tumour sup-
pressor phosphatase, PTEN: evidence
for activation by anionic phospho-
lipids. Biochem. J. 371, 947–955.
Meadows, S. A., Vega, F., Kashishian, A.,
Johnson, D., Diehl, V., Miller, L. L.,
Younes, A., and Lannutti, B. J. (2012).
PI3Kdelta inhibitor, GS-1101 (CAL-
101), attenuates pathway signaling,
induces apoptosis, and overcomes
signals from the microenvironment
in cellular models of Hodgkin lym-
phoma. Blood 119, 1897–1900.
Mikhalap, S. V., Shlapatska, L. M.,
Yurchenko, O. V., Yurchenko, M.
Y., Berdova, G. G., Nichols, K.
E., Clark, E. A., and Sidorenko,
S. P. (2004). The adaptor protein
SH2D1A regulates signaling through
CD150 (SLAM) in B cells. Blood 104,
4063–4070.
Miletic, A. V., Anzelon-Mills, A. N.,
Mills, D. M., Omori, S. A., Pedersen,
I. M., Shin, D. M., Ravetch, J. V., Bol-
land, S., Morse, H. C. III, and Rickert,
R. C. (2010). Coordinate suppression
of B cell lymphoma by PTEN and
SHIP phosphatases. J. Exp. Med. 207,
2407–2420.
Motiwala, T., Datta, J., Kutay, H., Roy,
S., and Jacob, S. T. (2010). Lyn
kinase and ZAP70 are substrates of
PTPROt in B-cells: Lyn inactivation
by PTPROt sensitizes leukemia cells
to VEGF-R inhibitor pazopanib. J.
Cell. Biochem. 110, 846–856.
Motiwala, T., Majumder, S. Kutay, H.,
Smith, D. S., Neuberg, D. S., Lucas,
D. M., Byrd, J. C., Grever, M., and
Jacob, S. T. (2007). Methylation and
silencing of protein tyrosine phos-
phatase receptor type O in chronic
lymphocytic leukemia. Clin. Cancer
Res. 3174–3181.
Mukherjee, O.,Weingarten, L., Padberg,
I., Pracht, C., Sinha, R., Hochdor-
fer, T., Kuppig, S., Backofen, R.,
Reth, M., and Huber, M. (2012). The
SH2-domain of SHIP1 interacts with
the SHIP1 C-terminus: Impact on
SHIP1/Ig-alpha interaction. Biochim.
Biophys. Acta 1823, 206–214.
Muzio, M., Apollonio, B., Scielzo, C.,
Frenquelli, M., Vandoni, I., Boussio-
tis, V., Caligaris-Cappio, F., and Ghia,
P. (2008). Constitutive activation of
distinct BCR-signaling pathways in
a subset of CLL patients: a molec-
ular signature of anergy. Blood 112,
188–195.
Myers,M. P., Stolarov, J. P., Eng,C., Li, J.,
Wang, S. I.,Wigler,M.H., Parsons, R.,
and Tonks, N. K. (1997). P-TEN, the
tumor suppressor from human chro-
mosome 10q23, is a dual-speciﬁcity
phosphatase. Proc. Natl. Acad. Sci.
U.S.A. 94, 9052–9057.
Nambu, Y., Sugai, M., Gonda, H.,
Lee, C. G., Katakai, T., Agata, Y.,
Yokota, Y., and Shimizu, A. (2003).
Transcription-coupled events associ-
ating with immunoglobulin switch
region chromatin. Science 302, 2137–
2140.
Nashed, B. F., Zhang, T., Al-Alwan,
M., Srinivasan, G., Halayko, A. J.,
Okkenhaug, K., Vanhaesebroeck, B.,
Hayglass, K. T., and Marshall, A. J.
(2007). Role of the phosphoinosi-
tide 3-kinase p110delta in generation
of type 2 cytokine responses and
allergic airway inﬂammation. Eur. J.
Immunol. 37, 416–424.
Ni, M., MacFarlane, A. W. IV, Toft,
M., Lowell, C. A., Campbell, K.
S., and Hamerman, J. A. (2012).
B-cell adaptor for PI3K (BCAP) neg-
atively regulates Toll-like receptor sig-
naling through activation of PI3K.
Proc. Natl. Acad. Sci. U.S.A. 109,
267–272.
Niedermeier, M., Hennessy, B. T.,
Knight, Z. A., Henneberg, M., Hu,
J., Kurtova, A. V., Wierda, W.
G., Keating, M. J., Shokat, K. M.,
and Burger, J. A. (2009). Isoform-
selective phosphoinositide 3′-kinase
inhibitors inhibit CXCR4 signaling
and overcome stromal cell-mediated
drug resistance in chronic lympho-
cytic leukemia: a novel therapeutic
approach. Blood 113, 5549–5557.
Nishio, M., Watanabe, K., Sasaki, J.,
Taya, C., Takasuga, S., Iizuka, R.,
Balla, T., Yamazaki, M., Watanabe,
H., Itoh, R., Kuroda, S., Horie, Y.,
Forster, I., Mak, T. W., Yonekawa, H.,
Penninger, J. M., Kanaho, Y., Suzuki,
A., and Sasaki, T. (2007). Control
of cell polarity and motility by the
PtdIns(3,4,5)P3 phosphatase SHIP1.
Nat. Cell Biol. 9, 36–44.
Norris, F. A., and Majerus, P. W.
(1994). Hydrolysis of phosphatidyli-
nositol 3,4-bisphosphate by inosi-
tol polyphosphate 4-phosphatase iso-
lated by afﬁnity elution chromatogra-
phy. J. Biol. Chem. 269, 8716–8720.
Odriozola, L., Singh, G., Hoang, T.,
and Chan, A. M. (2007). Regulation
of PTEN activity by its carboxyl-
terminal autoinhibitory domain. J.
Biol. Chem. 282, 23306–23315.
Oettgen, H. C., and Geha, R. S.
(2001). IgE regulation and roles in
asthma pathogenesis. J. Allergy Clin.
Immunol. 107, 429–440.
Okada, T., Maeda, A., Iwamatsu,
A., Gotoh, K., and Kurosaki, T.
(2000). BCAP: the tyrosine kinase
substrate that connects B cell receptor
to phosphoinositide 3-kinase activa-
tion. Immunity 13, 817–827.
Okkenhaug, K., Bilancio, A., Farjot, G.,
Priddle, H., Sancho, S., Peskett, E.,
Pearce, W., Meek, S. E., Salpekar, A.,
Waterﬁeld, M. D., Smith, A. J., and
Vanhaesebroeck, B. (2002). Impaired
B and T cell antigen receptor signal-
ing in p110delta PI 3-kinase mutant
mice. Science 297, 1031–1034.
Okkenhaug, K., and Fruman, D. A.
(2010). PI3Ks in lymphocyte sig-
naling and development. Curr. Top.
Microbiol. Immunol. 346, 57–85.
Okkenhaug, K., and Vanhaesebroeck, B.
(2003). PI3K in lymphocyte develop-
ment, differentiation and activation.
Nat. Rev. Immunol. 3, 317–330.
Omori, S. A., Cato, M. H., Anzelon-
Mills, A., Puri, K. D., Shapiro-
Shelef, M., Calame, K., and Rickert,
R. C. (2006). Regulation of class-
switch recombination andplasma cell
differentiation by phosphatidylinosi-
tol 3-kinase signaling. Immunity 25,
545–557.
www.frontiersin.org August 2012 | Volume 3 | Article 224 | 17
“ﬁmmu-03-00224” — 2012/8/7 — 17:39 — page 18 — #18
Pauls et al. PI3K pathway in B cells
O’Neill, S. K., Getahun, A., Gauld,
S. B., Merrell, K. T., Tamir, I.,
Smith, M. J., Dal Porto, J. M., Li,
Q. Z., and Cambier, J. C. (2011).
Monophosphorylation of CD79a
and CD79b ITAM motifs initi-
ates a SHIP-1 phosphatase-mediated
inhibitory signaling cascade required
for B cell anergy. Immunity 35,
746–756.
Ong, C. J., Ming-Lum, A., Nodwell, M.,
Ghanipour, A., Yang, L., Williams, D.
E., Kim, J., Demirjian, L., Qasimi, P.,
Ruschmann, J., Cao, L. P., Ma, K.,
Chung, S. W., Duronio, V., Ander-
sen, R. J., Krystal, G., and Mui, A.
L. (2007). Small-molecule agonists of
SHIP1 inhibit the phosphoinositide
3-kinase pathway in hematopoietic
cells. Blood 110, 1942–1949.
Orchard, J. A., Ibbotson, R. E., Davis, Z.,
Wiestner, A., Rosenwald, A., Thomas,
P. W., Hamblin, T. J., Staudt, L. M.,
and Oscier, D. G. (2004). ZAP-70
expression and prognosis in chronic
lymphocytic leukaemia. Lancet 363,
105–111.
O’Rourke, L. M., Tooze, R., Turner,
M., Sandoval, D. M., Carter, R. H.,
Tybulewicz, V. L., and Fearon, D.
T. (1998). CD19 as a membrane-
anchored adaptor protein of B lym-
phocytes: costimulation of lipid and
protein kinases by recruitment ofVav.
Immunity 8, 635–645.
Pacini, S., Pellegrini, M., Migliaccio,
E., Patrussi, L., Ulivieri, C., Ven-
tura, A., Carraro, F., Naldini, A.,
Lanfrancone, L., Pelicci, P., and Bal-
dari, C. T. (2004). p66SHC promotes
apoptosis and antagonizes mitogenic
signaling in T cells. Mol. Cell. Biol. 24,
1747–1757.
Palomero, T., Sulis, M. L., Cortina,
M., Real, P. J., Barnes, K., Cio-
fani, M., Caparros, E., Buteau, J.,
Brown, K., Perkins, S. L., Bhagat, G.,
Agarwal, A. M., Basso, G., Castillo,
M., Nagase, S., Cordon-Cardo, C.,
Parsons, R., Zuniga-Pﬂucker, J. C.,
Dominguez, M., and Ferrando, A.
A. (2007). Mutational loss of PTEN
induces resistance to NOTCH1 inhi-
bition in T-cell leukemia. Nat. Med.
13, 1203–1210.
Patke, A., Mecklenbrauker, I.,
Erdjument-Bromage, H., Tempst,
P., and Tarakhovsky, A. (2006).
BAFF controls B cell metabolic
ﬁtness through a PKC beta- and
Akt-dependent mechanism. J. Exp.
Med. 203, 2551–2562.
Pedersen, I. M., Otero, D., Kao, E.,
Miletic, A. V., Hother, C., Ralfki-
aer, E., Rickert, R. C., Gronbaek,
K., and David, M. (2009). Onco-
miR-155 targets SHIP1 to promote
TNFalpha-dependent growth of B
cell lymphomas. EMBO Mol. Med. 1,
288–295.
Phee, H., Jacob, A., and Coggeshall, K.
M. (2000). Enzymatic activity of the
Src homology 2 domain-containing
inositol phosphatase is regulated by
a plasma membrane location. J. Biol.
Chem. 275, 19090–19097.
Phee, H., Rodgers, W., and Coggeshall,
K. M. (2001). Visualization of nega-
tive signaling inB cells by quantitative
confocal microscopy. Mol. Cell. Biol.
21, 8615–8625.
Philippen, A., Diener, S., Zenz, T.,
Dohner, H., Stilgenbauer, S., and
Mertens, D. (2010). SYK carries no
activating pointmutations in patients
with chronic lymphocytic leukaemia
(CLL). Br. J. Haematol. 150,
633–636.
Plate, J. M. (2004). PI3-kinase regu-
lates survival of chronic lymphocytic
leukemia B-cells by preventing cas-
pase 8 activation. Leuk. Lymphoma
45, 1519–1529.
Ponader, S., Chen, S. S., Buggy, J. J., Bal-
akrishnan, K., Gandhi, V.,Wierda,W.
G., Keating, M. J., O’Brien, S., Chio-
razzi, N., and Burger, J. A. (2012).
The Bruton tyrosine kinase inhibitor
PCI-32765 thwarts chronic lympho-
cytic leukemia cell survival and tissue
homing in vitro and in vivo. Blood
119, 1182–1189.
Ramadani, F., Bolland, D. J., Garcon,
F., Emery, J. L., Vanhaesebroeck, B.,
Corcoran, A. E., and Okkenhaug, K.
(2010). ThePI3K isoformsp110alpha
and p110delta are essential for pre-
B cell receptor signaling and B cell
development. Sci. Signal. 3, ra60.
Rao, E., Jiang, C., Ji, M., Huang, X.,
Iqbal, J., Lenz, G., Wright, G., Staudt,
L. M., Zhao, Y., McKeithan, T. W.,
Chan, W. C., and Fu, K. (2011). The
miRNA-17 approximately 92 clus-
ter mediates chemoresistance and
enhances tumor growth in man-
tle cell lymphoma via PI3K/AKT
pathway activation. Leukemia 26,
1064–1072.
Rassenti, L. Z., Huynh, L., Toy, T. L.,
Chen, L., Keating, M. J., Gribben,
J. G., Neuberg, D. S., Flinn, I. W.,
Rai, K. R., Byrd, J. C., Kay, N. E.,
Greaves, A., Weiss, A., and Kipps,
T. J. (2004). ZAP-70 compared with
immunoglobulin heavy-chain gene
mutation status as a predictor of
disease progression in chronic lym-
phocytic leukemia. N. Engl. J. Med.
351, 893–901.
Rawlings, D. J., Saffran, D. C., Tsukada,
S., Largaespada, D. A., Grimaldi, J.
C., Cohen, L., Mohr, R. N., Bazan,
J. F., Howard, M., and Copeland,
N. G. (1993). Mutation of unique
region of Bruton’s tyrosine kinase in
immunodeﬁcient XID mice. Science
261, 358–361.
Raynaud, F. I., Eccles, S., Clarke, P. A.,
Hayes, A., Nutley, B., Alix, S., Henley,
A., Di-Stefano, F., Ahmad, Z., Guil-
lard, S., Bjerke, L. M., Kelland, L.,
Valenti, M., Patterson, L., Gowan, S.,
deHavenBrandon,A.,Hayakawa,M.,
Kaizawa, H., Koizumi, T., Ohishi, T.,
Patel, S., Saghir, N., Parker, P., Water-
ﬁeld, M., and Workman, P. (2007).
Pharmacologic characterization of a
potent inhibitor of class I phos-
phatidylinositide 3-kinases. Cancer
Res. 67, 5840–5850.
Reif, K., Okkenhaug, K., Sasaki, T., Pen-
ninger, J. M., Vanhaesebroeck, B.,
and Cyster, J. G. (2004). Cutting
edge: differential roles for phospho-
inositide 3-kinases, p110gamma and
p110delta, in lymphocyte chemo-
taxis and homing. J. Immunol. 173,
2236–2240.
Reth, M. (2002). Hydrogen peroxide
as second messenger in lymphocyte
activation. Nat. Immunol. 3, 1129–
1134.
Rickert, R. C., Rajewsky, K., and
Roes, J. (1995). Impairment of T-cell-
dependent B-cell responses and B-1
cell development in CD19-deﬁcient
mice. Nature 376, 352–355.
Ringshausen, I., Schneller, F., Bogner,
C., Hipp, S., Duyster, J., Peschel,
C., and Decker, T. (2002). Constitu-
tively activated phosphatidylinositol-
3 kinase (PI-3K) is involved in the
defect of apoptosis in B-CLL: associa-
tionwith protein kinaseCdelta. Blood
100, 3741–3748.
Rodriguez-Viciana, P., Sabatier, C.,
and McCormick, F. (2004). Signal-
ing speciﬁcity by Ras family GTPases
is determined by the full spectrum of
effectors they regulate. Mol. Cell. Biol.
24, 4943–4954.
Rodriguez-Viciana, P., Warne, P. H.,
Dhand, R., Vanhaesebroeck, B.,
Gout, I., Fry, M. J., Waterﬁeld,
M. D., and Downward, J. (1994).
Phosphatidylinositol-3-OH kinase as
a direct target of Ras. Nature 370,
527–532.
Rolf, J., Bell, S. E., Kovesdi, D., Janas,
M. L., Soond, D. R., Webb, L. M.,
Santinelli, S., Saunders, T., Hebeis,
B., Killeen, N., Okkenhaug, K., and
Turner, M. (2010). Phosphoinositide
3-kinase activity in T cells regulates
the magnitude of the germinal center
reaction. J. Immunol. 185, 4042–
4052.
Rosati, E., Sabatini, R., Rampino, G.,
Tabilio, A., Di Ianni, M., Fettuc-
ciari, K., Bartoli, A., Coaccioli, S.,
Screpanti, I., and Marconi, P. (2009).
Constitutively activated Notch sig-
naling is involved in survival and
apoptosis resistance of B-CLL cells.
Blood 113, 856–865.
Ross, S. H., Lindsay, Y., Safrany, S. T.,
Lorenzo,O.,Villa, F., Toth, R., Clague,
M. J., Downes, C. P., and Leslie, N.
R. (2007). Differential redox regula-
tionwithin the PTP superfamily. Cell.
Signal. 19, 1521–1530.
Rossi, D., Rasi, S., Fabbri, G., Spina, V.,
Fangazio, M., Forconi, F., Marasca,
R., Laurenti, L., Bruscaggin, A., Cerri,
M., Monti, S., Cresta, S., Fama, R.,
De Paoli, L., Bulian, P., Gattei, V.,
Guarini, A., Deaglio, S., Capello, D.,
Rabadan, R., Pasqualucci, L., Dalla-
Favera, R., Foa, R., and Gaidano, G.
(2012). Mutations of NOTCH1are an
independent predictor of survival in
chronic lymphocytic leukemia. Blood
119, 521–529.
Ruschmann, J., Ho, V., Antignano, F.,
Kuroda, E., Lam, V., Ibaraki, M.,
Snyder, K., Kim, C., Flavell, R. A.,
Kawakami, T., Sly, L., Turhan, A.
G., and Krystal, G. (2010). Tyro-
sine phosphorylation of SHIP pro-
motes its proteasomal degradation.
Exp. Hematol. 38, 392–402, 402.e1.
Sadhu, C., Masinovsky, B., Dick, K.,
Sowell, C. G., and Staunton, D. E.
(2003). Essential role of phospho-
inositide 3-kinase delta in neutrophil
directional movement. J. Immunol.
170, 2647–2654.
Sakai, A., Thieblemont, C., Wellmann,
A., Jaffe, E. S., and Raffeld, M. (1998).
PTEN gene alterations in lymphoid
neoplasms. Blood 92, 3410–3415.
Salim, K., Bottomley, M. J., Querfurth,
E., Zvelebil, M. J., Gout, I., Scaife,
R., Margolis, R. L., Gigg, R., Smith,
C. I., Driscoll, P. C., Waterﬁeld, M.
D., and Panayotou, G. (1996). Dis-
tinct speciﬁcity in the recognition of
phosphoinositides by the pleckstrin
homology domains of dynamin and
Bruton’s tyrosine kinase. EMBO J. 15,
6241–6250.
Sasaki, T., Irie-Sasaki, J., Jones, R. G.,
Oliveira-dos-Santos, A. J., Stanford,
W. L., Bolon, B.,Wakeham,A., Itie,A.,
Bouchard, D., Kozieradzki, I., Joza,
N., Mak, T. W., Ohashi, P. S., Suzuki,
A., andPenninger, J.M. (2000). Func-
tion of PI3Kgamma in thymocyte
development, T cell activation, and
neutrophil migration. Science 287,
1040–1046.
Sato, T. K., Overduin, M., and
Emr, S. D. (2001). Location, loca-
tion, location: membrane targeting
directed by PX domains. Science 294,
1881–1885.
Scheid, M. P., Huber, M., Damen, J.
E., Hughes, M., Kang, V., Neilsen,
P., Prestwich, G. D., Krystal, G., and
Duronio, V. (2002). Phosphatidyli-
nositol (3,4,5)P3 is essential but
Frontiers in Immunology | B Cell Biology August 2012 | Volume 3 | Article 224 | 18
“ﬁmmu-03-00224” — 2012/8/7 — 17:39 — page 19 — #19
Pauls et al. PI3K pathway in B cells
not sufﬁcient for protein kinase B
(PKB) activation; phosphatidyli-
nositol (3,4)P2 is required for
PKB phosphorylation at Ser-473:
studies using cells from SH2-
containing inositol-5-phosphatase
knockout mice. J. Biol. Chem. 277,
9027–9035.
Severin, S., Gratacap, M. P., Lenain,
N., Alvarez, L., Hollande, E., Pen-
ninger, J. M., Gachet, C., Plantavid,
M., and Payrastre, B. (2007). Deﬁ-
ciency of Src homology 2 domain-
containing inositol 5-phosphatase 1
affects platelet responses and throm-
bus growth. J. Clin. Invest. 117,
944–952.
Shehata, M., Schnabl, S., Demirtas, D.,
Hilgarth, M., Hubmann, R., Ponath,
E., Badrnya, S., Lehner, C., Hoelbl, A.,
Duechler, M., Gaiger, A., Zielinski,
C., Schwarzmeier, J. D., and Jaeger,
U. (2010). Reconstitution of PTEN
activity by CK2 inhibitors and inter-
ference with the PI3-K/Akt cascade
counteract the antiapoptotic effect
of human stromal cells in chronic
lymphocytic leukemia. Blood 116,
2513–2521.
Spagnuolo, C., Cerella, C., Russo, M.,
Chateauvieux, S., Diederich, M., and
Russo, G. L. (2011). Quercetin down-
regulates Mcl-1 by acting on mRNA
stability and protein degradation. Br.
J. Cancer 105, 221–230.
Srinivasan, L., Sasaki, Y., Calado, D.
P., Zhang, B., Paik, J. H., DePinho,
R. A., Kutok, J. L., Kearney, J.
F., Otipoby, K. L., and Rajewsky,
K. (2009). PI3 kinase signals BCR-
dependentmature B cell survival. Cell
139, 573–586.
Stavnezer, J., Radcliffe, G., Lin,
Y. C., Nietupski, J., Berggren,
L., Sitia, R., and Severinson,
E. (1988). Immunoglobulin heavy-
chain switching may be directed by
prior induction of transcripts from
constant-region genes. Proc. Natl.
Acad. Sci. U.S.A. 85, 7704–7708.
Suzuki, A., Kaisho, T., Ohishi, M.,
Tsukio-Yamaguchi, M., Tsubata, T.,
Koni, P. A., Sasaki, T., Mak, T.
W., and Nakano, T. (2003). Critical
roles of Pten in B cell homeosta-
sis and immunoglobulin class switch
recombination. J. Exp. Med. 197,
657–667.
Suzuki, H., Terauchi, Y., Fujiwara, M.,
Aizawa, S., Yazaki, Y., Kadowaki,
T., and Koyasu, S. (1999). Xid-like
immunodeﬁciency in mice with dis-
ruption of the p85alpha subunit of
phosphoinositide 3-kinase. Science
283, 390–392.
Tamir, I., Stolpa, J. C., Helgason, C. D.,
Nakamura, K., Bruhns, P., Daeron,
M., and Cambier, J. C. (2000). The
RasGAP-binding protein p62dok is
a mediator of inhibitory Fcgam-
maRIIB signals in B cells. Immunity
12, 347–358.
Taniguchi, C. M., Tran, T. T., Kondo, T.,
Luo, J., Ueki, K., Cantley, L. C., and
Kahn, C. R. (2006). Phosphoinositide
3-kinase regulatory subunit p85alpha
suppresses insulin action via positive
regulation of PTEN. Proc. Natl. Acad.
Sci. U.S.A. 103, 12093–12097.
Thompson, A. A., Talley, J. A., Do, H.
N., Kagan, H. L., Kunkel, L., Beren-
son, J., Cooper, M. D., Saxon, A., and
Wall, R. (1997). Aberrations of the
B-cell receptor B29 (CD79b) gene in
chronic lymphocytic leukemia. Blood
90, 1387–1394.
Tolar, P., Sohn, H. W., and Pierce, S.
K. (2005). The initiation of antigen-
induced B cell antigen receptor sig-
naling viewed in living cells by ﬂu-
orescence resonance energy transfer.
Nat. Immunol. 6, 1168–1176.
Torres, J., and Pulido, R. (2001). The
tumor suppressor PTEN is phos-
phorylated by the protein kinase
CK2 at its C terminus. Implications
for PTEN stability to proteasome-
mediated degradation. J. Biol. Chem.
276, 993–998.
Trentin, L., Frasson, M., Donella-
Deana,A., Frezzato, F., Pagano, M. A.,
Tibaldi, E., Gattazzo, C., Zambello,
R., Semenzato, G., and Brunati, A. M.
(2008). Geldanamycin-induced Lyn
dissociation from aberrant Hsp90-
stabilized cytosolic complex is an
early event in apoptotic mechanisms
in B-chronic lymphocytic leukemia.
Blood 112, 4665–4674.
Tridandapani, S., Kelley, T., Prad-
han, M., Cooney, D., Justement, L.
B., and Coggeshall, K. M. (1997).
Recruitment and phosphorylation
of SH2-containing inositol phos-
phatase and Shc to the B-cell Fc
gamma immunoreceptor tyrosine-
based inhibition motif peptide motif.
Mol. Cell. Biol. 17, 4305–4311.
Trotman, L. C., Wang, X., Alimonti,
A., Chen, Z., Teruya-Feldstein, J.,
Yang, H., Pavletich, N. P., Carver,
B. S., Cordon-Cardo, C., Erdjument-
Bromage, H., Tempst, P., Chi, S. G.,
Kim, H. J., Misteli, T., Jiang, X., and
Pandolﬁ, P. P. (2007). Ubiquitina-
tion regulates PTEN nuclear import
and tumor suppression. Cell 128,
141–156.
Troutman, T. D., Hu, W., Fulenchek, S.,
Yamazaki, T., Kurosaki, T., Bazan, J.
F., and Pasare, C. (2012). Role for
B-cell adapter for PI3K (BCAP) as
a signaling adapter linking Toll-like
receptors (TLRs) to serine/threonine
kinases PI3K/Akt. Proc. Natl. Acad.
Sci. U.S.A. 109, 273–278.
Tuveson, D. A., Carter, R. H., Soltoff, S.
P., and Fearon, D. T. (1993). CD19
of B cells as a surrogate kinase insert
region to bind phosphatidylinositol
3-kinase. Science 260, 986–989.
Tze, L. E., Schram, B. R., Lam, K.
P., Hogquist, K. A., Hippen, K. L.,
Liu, J., Shinton, S. A., Otipoby,
K. L., Rodine, P. R., Vegoe, A. L.,
Kraus, M., Hardy, R. R., Schlissel,
M. S., Rajewsky, K., and Behrens,
T. W. (2005). Basal immunoglobulin
signaling actively maintains develop-
mental stage in immature B cells.
PLoS Biol. 3, e82. doi: 10.1371/jour-
nal.pbio.0030082
Van der Kaay, J., Beck, M., Gray, A., and
Downes, C. P. (1999). Distinct phos-
phatidylinositol 3-kinase lipid prod-
ucts accumulate upon oxidative and
osmotic stress and lead to different
cellular responses. J. Biol. Chem. 274,
35963–35968.
Vanderwinden, J. M., Wang, D., Pater-
notte, N., Mignon, S., Isozaki, K.,
and Erneux, C. (2006). Differences
in signaling pathways and expression
level of the phosphoinositide phos-
phatase SHIP1 between two onco-
genic mutants of the receptor tyro-
sine kinase KIT. Cell. Signal. 18,
661–669.
Vanhaesebroeck, B., Welham, M. J.,
Kotani, K., Stein, R., Warne, P. H.,
Zvelebil, M. J., Higashi, K., Volinia,
S., Downward, J., and Waterﬁeld,
M. D. (1997). p110delta, a novel
phosphoinositide 3-kinase in leuko-
cytes. Proc. Natl. Acad. Sci. U.S.A. 94,
4330–4335.
Vazquez, F., Grossman, S. R., Taka-
hashi, Y., Rokas, M. V., Nakamura,
N., and Sellers, W. R. (2001). Phos-
phorylation of the PTEN tail acts as
an inhibitory switch by preventing its
recruitment into a protein complex.
J. Biol. Chem. 276, 48627–48630.
Vazquez, F., Ramaswamy, S., Nakamura,
N., and Sellers, W. R. (2000). Phos-
phorylation of the PTEN tail regu-
lates protein stability and function.
Mol. Cell. Biol. 20, 5010–5018.
Verkoczy, L., Duong, B., Skog, P.,
Ait-Azzouzene, D., Puri, K., Vela,
J. L., and Nemazee, D. (2007).
Basal B cell receptor-directed phos-
phatidylinositol 3-kinase signaling
turns off RAGs and promotes B cell-
positive selection. J. Immunol. 178,
6332–6341.
Vigorito, E., Bardi, G., Glassford,
J., Lam, E. W., Clayton, E., and
Turner, M. (2004). Vav-dependent
and vav-independent phosphatidyli-
nositol 3-kinase activation in murine
B cells determined by the nature
of the stimulus. J. Immunol. 173,
3209–3214.
Wang, X., Trotman, L. C., Koppie, T.,
Alimonti,A., Chen, Z.,Gao, Z.,Wang,
J., Erdjument-Bromage, H., Tempst,
P., Cordon-Cardo, C., Pandolﬁ, P. P.,
and Jiang, X. (2007). NEDD4-1 is a
proto-oncogenic ubiquitin ligase for
PTEN. Cell 128, 129–139.
Wang, Y., Brooks, S. R., Li, X., Anzelon,
A. N., Rickert, R. C., and Carter, R. H.
(2002). The physiologic role of CD19
cytoplasmic tyrosines. Immunity 17,
501–514.
Wickremasinghe, R. G., Ganeshaguru,
K., Jones, D. T., Lindsay, C.,
Spanswick, V. J., Hartley, J. A.,
Wadhwa, M., Thorpe, R., Hoff-
brand, A. V., Prentice, H. G., and
Mehta, A. B. (2001). Autologous
plasma activates Akt/protein kinase
B and enhances basal survival and
resistance to DNA damage-induced
apoptosis in B-chronic lymphocytic
leukaemia cells. Br. J. Haematol. 114,
608–615.
Wullschleger, S., Wasserman, D. H.,
Gray, A., Sakamoto, K., and Alessi, D.
R. (2011). Role of TAPP1 and TAPP2
adaptor binding to PtdIns(3,4)P2 in
regulating insulin sensitivity deﬁned
by knock-in analysis. Biochem. J. 434,
265–274.
Yamazaki, T., Takeda, K., Gotoh,
K., Takeshima, H., Akira, S.,
and Kurosaki, T. (2002). Essential
immunoregulatory role for BCAP in
B cell development and function. J.
Exp. Med. 195, 535–545.
Yu, J., Wjasow, C., and Backer,
J. M. (1998a). Regulation of the
p85/p110alpha phosphatidylinositol
3′-kinase. Distinct roles for the
n-terminal and c-terminal SH2
domains. J. Biol. Chem. 273, 30199–
30203.
Yu, J., Zhang, Y., McIlroy, J., Rordorf-
Nikolic, T., Orr, G. A., and Backer,
J. M. (1998b). Regulation of the
p85/p110 phosphatidylinositol 3′-
kinase: stabilization and inhibition
of the p110alpha catalytic subunit by
the p85 regulatory subunit. Mol. Cell.
Biol. 18, 1379–1387.
Zamorano, J., Wang, H. Y., Wang, L.
M., Pierce, J. H., and Keegan, A. D.
(1996). IL-4 protects cells from apop-
tosis via the insulin receptor substrate
pathway and a second independent
signaling pathway. J. Immunol. 157,
4926–4934.
Zhang, J., Ravichandran, K. S., and
Garrison, J. C. (2010a). A key role
for the phosphorylation of Ser440
by the cyclic AMP-dependent pro-
tein kinase in regulating the activ-
ity of the Src homology 2 domain-
containing Inositol 5′-phosphatase
(SHIP1). J. Biol. Chem. 285,
34839–34849.
www.frontiersin.org August 2012 | Volume 3 | Article 224 | 19
“ﬁmmu-03-00224” — 2012/8/7 — 17:39 — page 20 — #20
Pauls et al. PI3K pathway in B cells
Zhang, T. T., Al-Alwan, M., and Mar-
shall, A. J. (2010b). The pleckstrin
homology domain adaptor protein
Bam32/DAPP1 is required for germi-
nal center progression. J. Immunol.
184, 164–172.
Zhang, J., Walk, S. F., Ravichandran,
K. S., and Garrison, J. C. (2009a).
Regulation of the Src homology
2 domain-containing inositol 5′-
phosphatase (SHIP1) by the cyclic
AMP-dependent protein kinase. J.
Biol. Chem. 284, 20070–20078.
Zhang, T. T., Li, H., Cheung, S. M.,
Costantini, J. L., Hou, S., Al-Alwan,
M., and Marshall, A. J. (2009b).
Phosphoinositide 3-kinase-regulated
adapters in lymphocyte activation.
Immunol. Rev. 232, 255–272.
Zhang, T. T., Makondo, K. J., and
Marshall, A. J. (2012). p110delta
phosphoinositide 3-kinase represses
IgE switch by potentiating BCL6
expression. J. Immunol. 188,
3700–3708.
Zhang, T. T., Okkenhaug, K., Nashed,
B. F., Puri, K. D., Knight, Z.
A., Shokat, K. M., Vanhaese-
broeck, B., and Marshall, A. J.
(2008). Genetic or pharmaceutical
blockade of p110delta phosphoinosi-
tide 3-kinase enhances IgE produc-
tion. J. Allergy Clin. Immunol. 122,
811–819.
Zhang, X., Vadas, O., Perisic, O., Ander-
son, K. E., Clark, J., Hawkins, P.
T., Stephens, L. R., and Williams,
R. L. (2011). Structure of lipid
kinase p110beta/p85beta elucidates
an unusual SH2-domain-mediated
inhibitory mechanism. Mol. Cell 41,
567–578.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or ﬁnancial relationships that
could be construed as a potential
conﬂict of interest.
Received: 30 April 2012; paper pending
published: 17 May 2012; accepted: 10
July 2012; published online: 09 August
2012.
Citation: Pauls SD, Lafarge ST, Lan-
dego I, Zhang T and Marshall AJ (2012)
The phosphoinositide 3-kinase signaling
pathway in normal andmalignant B cells:
activation mechanisms, regulation, and
impact on cellular functions. Front.
Immun. 3:224. doi: 10.3389/ﬁmmu.
2012.00224
This article was submitted to Frontiers in
B Cell Biology, a specialty of Frontiers in
Immunology.
Copyright © 2012 Pauls, Lafarge, Lan-
dego, Zhang and Marshall. This is
an open-access article distributed under
the terms of the Creative Commons
Attribution License, which permits use,
distribution and reproduction in other
forums, provided the original authors and
source are credited and subject to any
copyright notices concerning any third-
party graphics etc.
Frontiers in Immunology | B Cell Biology August 2012 | Volume 3 | Article 224 | 20
